<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-MedLine.d161">
    <sentence id="DDI-MedLine.d161.s0" text="Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.&#xd;&#xa;">
        <entity id="DDI-MedLine.d161.s0.e0" charOffset="114-117"
            type="drug_n" text="MPTP"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s1" text="Degeneration of the dopaminergic nigrostriatal system and of noradrenergic neurons in the locus coeruleus are important pathological features of Parkinson's disease. "/>
    <sentence id="DDI-MedLine.d161.s2" text="There is an urgent need to develop therapies that slow down the progression of neurodegeneration in Parkinson's disease. "/>
    <sentence id="DDI-MedLine.d161.s3" text="In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ">
        <entity id="DDI-MedLine.d161.s3.e0" charOffset="106-153"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s3.e1" charOffset="281-324"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s3.p0" e1="DDI-MedLine.d161.s3.e0"
            e2="DDI-MedLine.d161.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s4" text="Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ">
        <entity id="DDI-MedLine.d161.s4.e0" charOffset="21-64"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s4.e1" charOffset="150-197"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s4.e2" charOffset="321-364"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s4.e3" charOffset="366-413"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s4.e4" charOffset="422-465"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s4.p0" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p1" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p2" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p3" e1="DDI-MedLine.d161.s4.e0"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p4" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p5" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p6" e1="DDI-MedLine.d161.s4.e1"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p7" e1="DDI-MedLine.d161.s4.e2"
            e2="DDI-MedLine.d161.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p8" e1="DDI-MedLine.d161.s4.e2"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d161.s4.p9" e1="DDI-MedLine.d161.s4.e3"
            e2="DDI-MedLine.d161.s4.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s5" text="After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ">
        <entity id="DDI-MedLine.d161.s5.e0" charOffset="18-61"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e1" charOffset="78-121"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e2" charOffset="200-243"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s5.e3" charOffset="245-292"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <pair id="DDI-MedLine.d161.s5.p0" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p1" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p2" e1="DDI-MedLine.d161.s5.e0"
            e2="DDI-MedLine.d161.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p3" e1="DDI-MedLine.d161.s5.e1"
            e2="DDI-MedLine.d161.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p4" e1="DDI-MedLine.d161.s5.e1"
            e2="DDI-MedLine.d161.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d161.s5.p5" e1="DDI-MedLine.d161.s5.e2"
            e2="DDI-MedLine.d161.s5.e3" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s6" text="These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ">
        <entity id="DDI-MedLine.d161.s6.e0" charOffset="349-392"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s6.e1" charOffset="394-441"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s6.e2" charOffset="467-510"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s6.p0" e1="DDI-MedLine.d161.s6.e0"
            e2="DDI-MedLine.d161.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d161.s6.p1" e1="DDI-MedLine.d161.s6.e0"
            e2="DDI-MedLine.d161.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s6.p2" e1="DDI-MedLine.d161.s6.e1"
            e2="DDI-MedLine.d161.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s7" text="The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ">
        <entity id="DDI-MedLine.d161.s7.e0" charOffset="4-51"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s7.e1" charOffset="100-143"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s7.p0" e1="DDI-MedLine.d161.s7.e0"
            e2="DDI-MedLine.d161.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s8" text="In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ">
        <entity id="DDI-MedLine.d161.s8.e0" charOffset="3-46"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s8.e1" charOffset="283-326"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d161.s8.e2" charOffset="328-375"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <pair id="DDI-MedLine.d161.s8.p0" e1="DDI-MedLine.d161.s8.e0"
            e2="DDI-MedLine.d161.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d161.s8.p1" e1="DDI-MedLine.d161.s8.e0"
            e2="DDI-MedLine.d161.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d161.s8.p2" e1="DDI-MedLine.d161.s8.e1"
            e2="DDI-MedLine.d161.s8.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s9" text="Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ">
        <entity id="DDI-MedLine.d161.s9.e0" charOffset="99-146"
            type="drug_n" text="3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"/>
        <entity id="DDI-MedLine.d161.s9.e1" charOffset="171-214"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"/>
        <pair id="DDI-MedLine.d161.s9.p0" e1="DDI-MedLine.d161.s9.e0"
            e2="DDI-MedLine.d161.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d161.s10" text="This suggests that the use of metabotropic glutamate receptor 5 antagonists may be a useful strategy to reduce degeneration of catecholaminergic neurons in Parkinson's disease."/>
    <sentence id="DDI-MedLine.d185.s0" text="Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.&#xd;&#xa;">
        <entity id="DDI-MedLine.d185.s0.e0" charOffset="10-21"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-MedLine.d185.s0.e1" charOffset="82-93"
            type="drug" text="panobinostat"/>
        <entity id="DDI-MedLine.d185.s0.e2" charOffset="96-101"
            type="drug" text="LBH589"/>
        <entity id="DDI-MedLine.d185.s0.e3" charOffset="122-150"
            type="group" text="histone deacetylase inhibitor"/>
        <pair id="DDI-MedLine.d185.s0.p0" e1="DDI-MedLine.d185.s0.e0"
            e2="DDI-MedLine.d185.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d185.s0.p1" e1="DDI-MedLine.d185.s0.e0"
            e2="DDI-MedLine.d185.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d185.s0.p2" e1="DDI-MedLine.d185.s0.e0"
            e2="DDI-MedLine.d185.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d185.s0.p3" e1="DDI-MedLine.d185.s0.e1"
            e2="DDI-MedLine.d185.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d185.s0.p4" e1="DDI-MedLine.d185.s0.e1"
            e2="DDI-MedLine.d185.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d185.s0.p5" e1="DDI-MedLine.d185.s0.e2"
            e2="DDI-MedLine.d185.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s1" text="Panobinostat is partly metabolized by CYP3A4 in vitro. ">
        <entity id="DDI-MedLine.d185.s1.e0" charOffset="0-11"
            type="drug" text="Panobinostat"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s2" text="This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.">
        <entity id="DDI-MedLine.d185.s2.e0" charOffset="61-72"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-MedLine.d185.s2.e1" charOffset="113-124"
            type="drug" text="panobinostat"/>
        <pair id="DDI-MedLine.d185.s2.p0" e1="DDI-MedLine.d185.s2.e0"
            e2="DDI-MedLine.d185.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s3" text="Patients received a single panobinostat oral dose on day 1, followed by 4  days wash-out period. ">
        <entity id="DDI-MedLine.d185.s3.e0" charOffset="27-38"
            type="drug" text="panobinostat"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s4" text="On days 5-9, ketoconazole was administered. ">
        <entity id="DDI-MedLine.d185.s4.e0" charOffset="13-24"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s5" text="On day 8, a single panobinostat dose was co-administered with ketoconazole. ">
        <entity id="DDI-MedLine.d185.s5.e0" charOffset="19-30"
            type="drug" text="panobinostat"/>
        <entity id="DDI-MedLine.d185.s5.e1" charOffset="62-73"
            type="drug" text="ketoconazole"/>
        <pair id="DDI-MedLine.d185.s5.p0" e1="DDI-MedLine.d185.s5.e0"
            e2="DDI-MedLine.d185.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s6" text="Panobinostat was administered as single agent three times a week on day 15 and onward. ">
        <entity id="DDI-MedLine.d185.s6.e0" charOffset="0-11"
            type="drug" text="Panobinostat"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s7" text="In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. ">
        <entity id="DDI-MedLine.d185.s7.e0" charOffset="19-30"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-MedLine.d185.s7.e1" charOffset="92-103"
            type="drug" text="panobinostat"/>
        <pair id="DDI-MedLine.d185.s7.p0" e1="DDI-MedLine.d185.s7.e0"
            e2="DDI-MedLine.d185.s7.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s8" text="No substantial change in T (max) or half-life was observed. "/>
    <sentence id="DDI-MedLine.d185.s9" text="No difference in panobinostat-pharmacokinetics between patients carrying CYP3A5*1/*3 and CYP3A5*3/*3 alleles was observed. ">
        <entity id="DDI-MedLine.d185.s9.e0" charOffset="17-28"
            type="drug" text="panobinostat"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s10" text="Most frequently reported adverse events were gastrointestinal related. "/>
    <sentence id="DDI-MedLine.d185.s11" text="Patients had asymptomatic hypophosphatemia (64%), and urine analysis suggested renal phosphate wasting. "/>
    <sentence id="DDI-MedLine.d185.s12" text="Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. ">
        <entity id="DDI-MedLine.d185.s12.e0" charOffset="21-32"
            type="drug" text="panobinostat"/>
        <entity id="DDI-MedLine.d185.s12.e1" charOffset="96-107"
            type="drug" text="panobinostat"/>
        <pair id="DDI-MedLine.d185.s12.p0" e1="DDI-MedLine.d185.s12.e0"
            e2="DDI-MedLine.d185.s12.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d185.s13" text="Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.">
        <entity id="DDI-MedLine.d185.s13.e0" charOffset="104-115"
            type="drug" text="panobinostat"/>
        <entity id="DDI-MedLine.d185.s13.e1" charOffset="176-187"
            type="drug" text="panobinostat"/>
        <pair id="DDI-MedLine.d185.s13.p0" e1="DDI-MedLine.d185.s13.e0"
            e2="DDI-MedLine.d185.s13.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s0" text="Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.&#xa;">
        <entity id="DDI-MedLine.d231.s0.e0" charOffset="21-32"
            type="drug" text="moxifloxacin"/>
        <entity id="DDI-MedLine.d231.s0.e1" charOffset="38-49"
            type="drug" text="lomefloxacin"/>
        <pair id="DDI-MedLine.d231.s0.p0" e1="DDI-MedLine.d231.s0.e0"
            e2="DDI-MedLine.d231.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s1" text="Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ">
        <entity id="DDI-MedLine.d231.s1.e0" charOffset="0-11"
            type="drug" text="Moxifloxacin"/>
        <entity id="DDI-MedLine.d231.s1.e1" charOffset="17-28"
            type="drug" text="lomefloxacin"/>
        <entity id="DDI-MedLine.d231.s1.e2" charOffset="34-60"
            type="group" text="fluoroquinolone antibiotics"/>
        <pair id="DDI-MedLine.d231.s1.p0" e1="DDI-MedLine.d231.s1.e0"
            e2="DDI-MedLine.d231.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d231.s1.p1" e1="DDI-MedLine.d231.s1.e0"
            e2="DDI-MedLine.d231.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d231.s1.p2" e1="DDI-MedLine.d231.s1.e1"
            e2="DDI-MedLine.d231.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s2" text="Fluoroquinolones are known to have interactions with drugs that are active in gastro intestinal tract. ">
        <entity id="DDI-MedLine.d231.s2.e0" charOffset="0-15"
            type="group" text="Fluoroquinolones"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s3" text="Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ">
        <entity id="DDI-MedLine.d231.s3.e0" charOffset="6-17"
            type="drug" text="moxifloxacin"/>
        <entity id="DDI-MedLine.d231.s3.e1" charOffset="36-51"
            type="group" text="fluoroquinolones"/>
        <entity id="DDI-MedLine.d231.s3.e2" charOffset="99-108"
            type="drug" text="sucralfate"/>
        <entity id="DDI-MedLine.d231.s3.e3" charOffset="111-117"
            type="brand" text="gelusil"/>
        <entity id="DDI-MedLine.d231.s3.e4" charOffset="120-131"
            type="drug" text="erythromycin"/>
        <entity id="DDI-MedLine.d231.s3.e5" charOffset="137-150"
            type="group" text="multi minerals"/>
        <pair id="DDI-MedLine.d231.s3.p0" e1="DDI-MedLine.d231.s3.e0"
            e2="DDI-MedLine.d231.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p1" e1="DDI-MedLine.d231.s3.e0"
            e2="DDI-MedLine.d231.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p2" e1="DDI-MedLine.d231.s3.e0"
            e2="DDI-MedLine.d231.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p3" e1="DDI-MedLine.d231.s3.e0"
            e2="DDI-MedLine.d231.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p4" e1="DDI-MedLine.d231.s3.e0"
            e2="DDI-MedLine.d231.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p5" e1="DDI-MedLine.d231.s3.e1"
            e2="DDI-MedLine.d231.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p6" e1="DDI-MedLine.d231.s3.e1"
            e2="DDI-MedLine.d231.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p7" e1="DDI-MedLine.d231.s3.e1"
            e2="DDI-MedLine.d231.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p8" e1="DDI-MedLine.d231.s3.e1"
            e2="DDI-MedLine.d231.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p9" e1="DDI-MedLine.d231.s3.e2"
            e2="DDI-MedLine.d231.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p10" e1="DDI-MedLine.d231.s3.e2"
            e2="DDI-MedLine.d231.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p11" e1="DDI-MedLine.d231.s3.e2"
            e2="DDI-MedLine.d231.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p12" e1="DDI-MedLine.d231.s3.e3"
            e2="DDI-MedLine.d231.s3.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p13" e1="DDI-MedLine.d231.s3.e3"
            e2="DDI-MedLine.d231.s3.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s3.p14" e1="DDI-MedLine.d231.s3.e4"
            e2="DDI-MedLine.d231.s3.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s4" text="The interaction was studied at neutral, acidic and basic conditions both at room temperature and 37  C. "/>
    <sentence id="DDI-MedLine.d231.s5" text="The effect of dissolution medium simulating various body environments with response to pH has been examined in order to elucidate the interactions. "/>
    <sentence id="DDI-MedLine.d231.s6" text="The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ">
        <entity id="DDI-MedLine.d231.s6.e0" charOffset="16-27"
            type="drug" text="moxifloxacin"/>
        <entity id="DDI-MedLine.d231.s6.e1" charOffset="33-44"
            type="drug" text="lomefloxacin"/>
        <pair id="DDI-MedLine.d231.s6.p0" e1="DDI-MedLine.d231.s6.e0"
            e2="DDI-MedLine.d231.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s7" text="It was seen that interaction of these fluoroquinolones was more at 37  C than at room temperature. ">
        <entity id="DDI-MedLine.d231.s7.e0" charOffset="38-53"
            type="group" text="fluoroquinolones"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s8" text="Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ">
        <entity id="DDI-MedLine.d231.s8.e0" charOffset="0-11"
            type="drug" text="Moxifloxacin"/>
        <entity id="DDI-MedLine.d231.s8.e1" charOffset="17-28"
            type="drug" text="Lomefloxacin"/>
        <entity id="DDI-MedLine.d231.s8.e2" charOffset="49-58"
            type="drug" text="sucralfate"/>
        <entity id="DDI-MedLine.d231.s8.e3" charOffset="64-70"
            type="brand" text="gelusil"/>
        <entity id="DDI-MedLine.d231.s8.e4" charOffset="101-112"
            type="drug" text="erythromycin"/>
        <entity id="DDI-MedLine.d231.s8.e5" charOffset="133-146"
            type="group" text="multi-minerals"/>
        <pair id="DDI-MedLine.d231.s8.p0" e1="DDI-MedLine.d231.s8.e0"
            e2="DDI-MedLine.d231.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p1" e1="DDI-MedLine.d231.s8.e0"
            e2="DDI-MedLine.d231.s8.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p2" e1="DDI-MedLine.d231.s8.e0"
            e2="DDI-MedLine.d231.s8.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p3" e1="DDI-MedLine.d231.s8.e0"
            e2="DDI-MedLine.d231.s8.e4" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p4" e1="DDI-MedLine.d231.s8.e0"
            e2="DDI-MedLine.d231.s8.e5" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p5" e1="DDI-MedLine.d231.s8.e1"
            e2="DDI-MedLine.d231.s8.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p6" e1="DDI-MedLine.d231.s8.e1"
            e2="DDI-MedLine.d231.s8.e3" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p7" e1="DDI-MedLine.d231.s8.e1"
            e2="DDI-MedLine.d231.s8.e4" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p8" e1="DDI-MedLine.d231.s8.e1"
            e2="DDI-MedLine.d231.s8.e5" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d231.s8.p9" e1="DDI-MedLine.d231.s8.e2"
            e2="DDI-MedLine.d231.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p10" e1="DDI-MedLine.d231.s8.e2"
            e2="DDI-MedLine.d231.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p11" e1="DDI-MedLine.d231.s8.e2"
            e2="DDI-MedLine.d231.s8.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p12" e1="DDI-MedLine.d231.s8.e3"
            e2="DDI-MedLine.d231.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p13" e1="DDI-MedLine.d231.s8.e3"
            e2="DDI-MedLine.d231.s8.e5" ddi="false"/>
        <pair id="DDI-MedLine.d231.s8.p14" e1="DDI-MedLine.d231.s8.e4"
            e2="DDI-MedLine.d231.s8.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s9" text="The study ensures the interaction of fluoroquinolones with selected class of drugs. ">
        <entity id="DDI-MedLine.d231.s9.e0" charOffset="37-52"
            type="group" text="fluoroquinolones"/>
    </sentence>
    <sentence id="DDI-MedLine.d231.s10" text="In order to achieve the effective therapeutic effect appropriate time intervals between administrations of drugs is essential."/>
    <sentence id="DDI-MedLine.d216.s0" text="Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.&#xd;&#xa;">
        <entity id="DDI-MedLine.d216.s0.e0" charOffset="17-26"
            type="drug" text="S-ketamine"/>
        <entity id="DDI-MedLine.d216.s0.e1" charOffset="45-56"
            type="drug" text="itraconazole"/>
        <entity id="DDI-MedLine.d216.s0.e2" charOffset="83-93"
            type="drug" text="ticlopidine"/>
        <pair id="DDI-MedLine.d216.s0.p0" e1="DDI-MedLine.d216.s0.e0"
            e2="DDI-MedLine.d216.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d216.s0.p1" e1="DDI-MedLine.d216.s0.e0"
            e2="DDI-MedLine.d216.s0.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d216.s0.p2" e1="DDI-MedLine.d216.s0.e1"
            e2="DDI-MedLine.d216.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s1" text="This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ">
        <entity id="DDI-MedLine.d216.s1.e0" charOffset="51-60"
            type="drug" text="S-ketamine"/>
        <entity id="DDI-MedLine.d216.s1.e1" charOffset="107-117"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-MedLine.d216.s1.e2" charOffset="143-154"
            type="drug" text="itraconazole"/>
        <pair id="DDI-MedLine.d216.s1.p0" e1="DDI-MedLine.d216.s1.e0"
            e2="DDI-MedLine.d216.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d216.s1.p1" e1="DDI-MedLine.d216.s1.e0"
            e2="DDI-MedLine.d216.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s1.p2" e1="DDI-MedLine.d216.s1.e1"
            e2="DDI-MedLine.d216.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s2" text="In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ">
        <entity id="DDI-MedLine.d216.s2.e0" charOffset="87-96"
            type="drug" text="S-ketamine"/>
        <entity id="DDI-MedLine.d216.s2.e1" charOffset="128-138"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-MedLine.d216.s2.e2" charOffset="162-173"
            type="drug" text="itraconazole"/>
        <pair id="DDI-MedLine.d216.s2.p0" e1="DDI-MedLine.d216.s2.e0"
            e2="DDI-MedLine.d216.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d216.s2.p1" e1="DDI-MedLine.d216.s2.e0"
            e2="DDI-MedLine.d216.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s2.p2" e1="DDI-MedLine.d216.s2.e1"
            e2="DDI-MedLine.d216.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s3" text="Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ">
        <entity id="DDI-MedLine.d216.s3.e0" charOffset="0-10"
            type="drug" text="Ticlopidine"/>
        <entity id="DDI-MedLine.d216.s3.e1" charOffset="134-141"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d216.s3.e2" charOffset="164-175"
            type="drug" text="itraconazole"/>
        <entity id="DDI-MedLine.d216.s3.e3" charOffset="220-229"
            type="drug" text="S-ketamine"/>
        <pair id="DDI-MedLine.d216.s3.p0" e1="DDI-MedLine.d216.s3.e0"
            e2="DDI-MedLine.d216.s3.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d216.s3.p1" e1="DDI-MedLine.d216.s3.e0"
            e2="DDI-MedLine.d216.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s3.p2" e1="DDI-MedLine.d216.s3.e0"
            e2="DDI-MedLine.d216.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d216.s3.p3" e1="DDI-MedLine.d216.s3.e1"
            e2="DDI-MedLine.d216.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s3.p4" e1="DDI-MedLine.d216.s3.e1"
            e2="DDI-MedLine.d216.s3.e3" ddi="false"/>
        <pair id="DDI-MedLine.d216.s3.p5" e1="DDI-MedLine.d216.s3.e2"
            e2="DDI-MedLine.d216.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s4" text="The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &amp;lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ">
        <entity id="DDI-MedLine.d216.s4.e0" charOffset="13-23"
            type="drug_n" text="norketamine"/>
        <entity id="DDI-MedLine.d216.s4.e1" charOffset="39-46"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d216.s4.e2" charOffset="94-104"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-MedLine.d216.s4.e3" charOffset="125-136"
            type="drug" text="itraconazole"/>
        <pair id="DDI-MedLine.d216.s4.p0" e1="DDI-MedLine.d216.s4.e0"
            e2="DDI-MedLine.d216.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d216.s4.p1" e1="DDI-MedLine.d216.s4.e0"
            e2="DDI-MedLine.d216.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s4.p2" e1="DDI-MedLine.d216.s4.e0"
            e2="DDI-MedLine.d216.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d216.s4.p3" e1="DDI-MedLine.d216.s4.e1"
            e2="DDI-MedLine.d216.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d216.s4.p4" e1="DDI-MedLine.d216.s4.e1"
            e2="DDI-MedLine.d216.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d216.s4.p5" e1="DDI-MedLine.d216.s4.e2"
            e2="DDI-MedLine.d216.s4.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s5" text="In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P &lt; 0.05). ">
        <entity id="DDI-MedLine.d216.s5.e0" charOffset="7-17"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-MedLine.d216.s5.e1" charOffset="23-34"
            type="drug" text="itraconazole"/>
        <pair id="DDI-MedLine.d216.s5.p0" e1="DDI-MedLine.d216.s5.e0"
            e2="DDI-MedLine.d216.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d216.s6" text="The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.">
        <entity id="DDI-MedLine.d216.s6.e0" charOffset="40-49"
            type="drug" text="S-ketamine"/>
        <entity id="DDI-MedLine.d216.s6.e1" charOffset="91-101"
            type="drug" text="ticlopidine"/>
        <pair id="DDI-MedLine.d216.s6.p0" e1="DDI-MedLine.d216.s6.e0"
            e2="DDI-MedLine.d216.s6.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s0" text="Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.&#xd;&#xa;">
        <entity id="DDI-MedLine.d180.s0.e0" charOffset="31-35"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s1" text="The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ">
        <entity id="DDI-MedLine.d180.s1.e0" charOffset="4-22"
            type="drug_n" text="3-Deazaneplanocin A"/>
        <entity id="DDI-MedLine.d180.s1.e1" charOffset="25-29"
            type="drug_n" text="DZNep"/>
        <pair id="DDI-MedLine.d180.s1.p0" e1="DDI-MedLine.d180.s1.e0"
            e2="DDI-MedLine.d180.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s2" text="Here, we examined its effects on multiple myeloma (MM) cells and found that, at 500 nM, it potently inhibited growth and induced apoptosis in 2 of 8 MM cell lines. "/>
    <sentence id="DDI-MedLine.d180.s3" text="RNA from un-treated and DZNep treated cells was profiled by Affymetrix HG-U133 Plus 2.0 microarray and genes with a significant change in gene expression were determined by significance analysis of microarray (SAM) testing. ">
        <entity id="DDI-MedLine.d180.s3.e0" charOffset="24-28"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s4" text="ALOX5 was the most down-regulated gene (5.8-fold) in sensitive cells and was expressed at low level in resistant cells. "/>
    <sentence id="DDI-MedLine.d180.s5" text="The results were corroborated by quantitative RT-PCR. "/>
    <sentence id="DDI-MedLine.d180.s6" text="Western-blot analysis indicated ALOX5 was highly expressed only in sensitive cell line H929 and greatly decreased upon DZNep treatment. ">
        <entity id="DDI-MedLine.d180.s6.e0" charOffset="119-123"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s7" text="Ectopic expression of ALOX5 reduced sensitivity to DZNep in H929 cells. ">
        <entity id="DDI-MedLine.d180.s7.e0" charOffset="51-55"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s8" text="Furthermore, down-regulation of ALOX5 by RNA interference could also induce apoptosis in H929. "/>
    <sentence id="DDI-MedLine.d180.s9" text="Gene expression analysis on MM patient dataset indicated ALOX5 expression was significantly higher in MM patients compared to normal plasma cells. "/>
    <sentence id="DDI-MedLine.d180.s10" text="We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ">
        <entity id="DDI-MedLine.d180.s10.e0" charOffset="46-50"
            type="drug_n" text="DZNep"/>
        <entity id="DDI-MedLine.d180.s10.e1" charOffset="92-96"
            type="drug_n" text="DZNep"/>
        <entity id="DDI-MedLine.d180.s10.e2" charOffset="102-108"
            type="drug_n" text="ABT-737"/>
        <entity id="DDI-MedLine.d180.s10.e3" charOffset="195-199"
            type="drug_n" text="DZNep"/>
        <pair id="DDI-MedLine.d180.s10.p0" e1="DDI-MedLine.d180.s10.e0"
            e2="DDI-MedLine.d180.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d180.s10.p1" e1="DDI-MedLine.d180.s10.e0"
            e2="DDI-MedLine.d180.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d180.s10.p2" e1="DDI-MedLine.d180.s10.e0"
            e2="DDI-MedLine.d180.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d180.s10.p3" e1="DDI-MedLine.d180.s10.e1"
            e2="DDI-MedLine.d180.s10.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d180.s10.p4" e1="DDI-MedLine.d180.s10.e1"
            e2="DDI-MedLine.d180.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d180.s10.p5" e1="DDI-MedLine.d180.s10.e2"
            e2="DDI-MedLine.d180.s10.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s11" text="Taken together, this study shows one of mechanisms of the DZNep efficacy on MM correlates with its ability to down-regulate the ALOX5 levels. ">
        <entity id="DDI-MedLine.d180.s11.e0" charOffset="58-62"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s12" text="In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ">
        <entity id="DDI-MedLine.d180.s12.e0" charOffset="13-17"
            type="drug_n" text="DZNep"/>
        <entity id="DDI-MedLine.d180.s12.e1" charOffset="106-112"
            type="drug_n" text="ABT-737"/>
        <entity id="DDI-MedLine.d180.s12.e2" charOffset="118-122"
            type="drug_n" text="DZNep"/>
        <pair id="DDI-MedLine.d180.s12.p0" e1="DDI-MedLine.d180.s12.e0"
            e2="DDI-MedLine.d180.s12.e1" ddi="false"/>
        <pair id="DDI-MedLine.d180.s12.p1" e1="DDI-MedLine.d180.s12.e0"
            e2="DDI-MedLine.d180.s12.e2" ddi="false"/>
        <pair id="DDI-MedLine.d180.s12.p2" e1="DDI-MedLine.d180.s12.e1"
            e2="DDI-MedLine.d180.s12.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d180.s13" text="These results suggest that DZNep may be exploited therapeutically for a subset of MM.">
        <entity id="DDI-MedLine.d180.s13.e0" charOffset="27-31"
            type="drug_n" text="DZNep"/>
    </sentence>
    <sentence id="DDI-MedLine.d208.s0" text="Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.">
        <entity id="DDI-MedLine.d208.s0.e0" charOffset="0-7"
            type="brand" text="Implanon"/>
        <entity id="DDI-MedLine.d208.s0.e1" charOffset="47-60"
            type="group" text="antiretroviral"/>
        <pair id="DDI-MedLine.d208.s0.p0" e1="DDI-MedLine.d208.s0.e0"
            e2="DDI-MedLine.d208.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d208.s1" text="Since its introduction in 1999, Implanon   remains one of the preferred contraceptive choices for many women as it offers a highly effective means of long-term contraception for three years that does not rely on adherence. ">
        <entity id="DDI-MedLine.d208.s1.e0" charOffset="32-39"
            type="brand" text="Implanon"/>
    </sentence>
    <sentence id="DDI-MedLine.d208.s2" text="Like all hormonal contraceptives, certain hepatic enzyme-inducing drugs may reduce its efficacy. ">
        <entity id="DDI-MedLine.d208.s2.e0" charOffset="9-31"
            type="group" text="hormonal contraceptives"/>
    </sentence>
    <sentence id="DDI-MedLine.d208.s3" text="We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.">
        <entity id="DDI-MedLine.d208.s3.e0" charOffset="59-72"
            type="group" text="antiretroviral"/>
        <entity id="DDI-MedLine.d208.s3.e1" charOffset="138-145"
            type="brand" text="Implanon"/>
        <pair id="DDI-MedLine.d208.s3.p0" e1="DDI-MedLine.d208.s3.e0"
            e2="DDI-MedLine.d208.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s0" text="Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.&#xd;&#xa;">
        <entity id="DDI-MedLine.d218.s0.e0" charOffset="0-13"
            type="group" text="Antidepressant"/>
        <entity id="DDI-MedLine.d218.s0.e1" charOffset="15-22"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d218.s0.p0" e1="DDI-MedLine.d218.s0.e0"
            e2="DDI-MedLine.d218.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s1" text="Bleeding is the most common and worrisome adverse effect of warfarin therapy. ">
        <entity id="DDI-MedLine.d218.s1.e0" charOffset="60-67"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s2" text="One of the factors that might increase bleeding risk is initiation of interacting drugs that potentiate warfarin. ">
        <entity id="DDI-MedLine.d218.s2.e0" charOffset="104-111"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s3" text="We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.">
        <entity id="DDI-MedLine.d218.s3.e0" charOffset="47-60"
            type="group" text="antidepressant"/>
        <entity id="DDI-MedLine.d218.s3.e1" charOffset="133-140"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d218.s3.p0" e1="DDI-MedLine.d218.s3.e0"
            e2="DDI-MedLine.d218.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s4" text="Medicaid claims data (1999-2005) were used to perform an observational case-control study nested within person-time exposed to warfarin in those   18 years.">
        <entity id="DDI-MedLine.d218.s4.e0" charOffset="127-134"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s5" text="In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ">
        <entity id="DDI-MedLine.d218.s5.e0" charOffset="18-25"
            type="drug" text="warfarin"/>
        <entity id="DDI-MedLine.d218.s5.e1" charOffset="69-76"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d218.s5.p0" e1="DDI-MedLine.d218.s5.e0"
            e2="DDI-MedLine.d218.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s6" text="The incidence rate of hospitalization for GI bleeding among warfarin users was 4.48 per 100 person-years (95% CI, 4.42-4.55). ">
        <entity id="DDI-MedLine.d218.s6.e0" charOffset="60-67"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s7" text="Each gastrointestinal bleeding cases was matched to 50 controls based on index date and state. "/>
    <sentence id="DDI-MedLine.d218.s8" text="Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ">
        <entity id="DDI-MedLine.d218.s8.e0" charOffset="0-7" type="drug" text="Warfarin"/>
        <entity id="DDI-MedLine.d218.s8.e1" charOffset="91-100"
            type="drug" text="citalopram"/>
        <entity id="DDI-MedLine.d218.s8.e2" charOffset="139-148"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d218.s8.e3" charOffset="187-196"
            type="drug" text="paroxetine"/>
        <entity id="DDI-MedLine.d218.s8.e4" charOffset="235-247"
            type="drug" text="amitriptyline"/>
        <pair id="DDI-MedLine.d218.s8.p0" e1="DDI-MedLine.d218.s8.e0"
            e2="DDI-MedLine.d218.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s8.p1" e1="DDI-MedLine.d218.s8.e0"
            e2="DDI-MedLine.d218.s8.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s8.p2" e1="DDI-MedLine.d218.s8.e0"
            e2="DDI-MedLine.d218.s8.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s8.p3" e1="DDI-MedLine.d218.s8.e0"
            e2="DDI-MedLine.d218.s8.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s8.p4" e1="DDI-MedLine.d218.s8.e1"
            e2="DDI-MedLine.d218.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d218.s8.p5" e1="DDI-MedLine.d218.s8.e1"
            e2="DDI-MedLine.d218.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d218.s8.p6" e1="DDI-MedLine.d218.s8.e1"
            e2="DDI-MedLine.d218.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d218.s8.p7" e1="DDI-MedLine.d218.s8.e2"
            e2="DDI-MedLine.d218.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d218.s8.p8" e1="DDI-MedLine.d218.s8.e2"
            e2="DDI-MedLine.d218.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d218.s8.p9" e1="DDI-MedLine.d218.s8.e3"
            e2="DDI-MedLine.d218.s8.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s9" text="Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ">
        <entity id="DDI-MedLine.d218.s9.e0" charOffset="5-15"
            type="drug" text="mirtazapine"/>
        <entity id="DDI-MedLine.d218.s9.e1" charOffset="57-64"
            type="drug" text="warfarin"/>
        <pair id="DDI-MedLine.d218.s9.p0" e1="DDI-MedLine.d218.s9.e0"
            e2="DDI-MedLine.d218.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s10" text="Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ">
        <entity id="DDI-MedLine.d218.s10.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-MedLine.d218.s10.e1" charOffset="29-38"
            type="drug" text="citalopram"/>
        <entity id="DDI-MedLine.d218.s10.e2" charOffset="41-50"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d218.s10.e3" charOffset="53-62"
            type="drug" text="paroxetine"/>
        <entity id="DDI-MedLine.d218.s10.e4" charOffset="65-77"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-MedLine.d218.s10.e5" charOffset="83-93"
            type="drug" text="mirtazapine"/>
        <pair id="DDI-MedLine.d218.s10.p0" e1="DDI-MedLine.d218.s10.e0"
            e2="DDI-MedLine.d218.s10.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s10.p1" e1="DDI-MedLine.d218.s10.e0"
            e2="DDI-MedLine.d218.s10.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s10.p2" e1="DDI-MedLine.d218.s10.e0"
            e2="DDI-MedLine.d218.s10.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s10.p3" e1="DDI-MedLine.d218.s10.e0"
            e2="DDI-MedLine.d218.s10.e4" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s10.p4" e1="DDI-MedLine.d218.s10.e0"
            e2="DDI-MedLine.d218.s10.e5" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d218.s10.p5" e1="DDI-MedLine.d218.s10.e1"
            e2="DDI-MedLine.d218.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p6" e1="DDI-MedLine.d218.s10.e1"
            e2="DDI-MedLine.d218.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p7" e1="DDI-MedLine.d218.s10.e1"
            e2="DDI-MedLine.d218.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p8" e1="DDI-MedLine.d218.s10.e1"
            e2="DDI-MedLine.d218.s10.e5" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p9" e1="DDI-MedLine.d218.s10.e2"
            e2="DDI-MedLine.d218.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p10" e1="DDI-MedLine.d218.s10.e2"
            e2="DDI-MedLine.d218.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p11" e1="DDI-MedLine.d218.s10.e2"
            e2="DDI-MedLine.d218.s10.e5" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p12" e1="DDI-MedLine.d218.s10.e3"
            e2="DDI-MedLine.d218.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p13" e1="DDI-MedLine.d218.s10.e3"
            e2="DDI-MedLine.d218.s10.e5" ddi="false"/>
        <pair id="DDI-MedLine.d218.s10.p14" e1="DDI-MedLine.d218.s10.e4"
            e2="DDI-MedLine.d218.s10.e5" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d218.s11" text="However, the elevated risk with mirtazapine suggests that a drug-drug interaction may not have been responsible for all of the observed increased risk.">
        <entity id="DDI-MedLine.d218.s11.e0" charOffset="32-42"
            type="drug" text="mirtazapine"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s0" text="Effects of CYP inhibitors on precocene I metabolism and toxicity in rat liver slices.&#xd;&#xa;">
        <entity id="DDI-MedLine.d189.s0.e0" charOffset="29-39"
            type="drug_n" text="precocene I"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s1" text="We present a comprehensive in vitro approach to assessing metabolism-mediated hepatotoxicity using male Sprague-Dawley rat liver slices incubated with the well characterized hepatotoxicant, precocene I, and inhibitors of cytochrome P450 (CYP) enzymes. ">
        <entity id="DDI-MedLine.d189.s1.e0" charOffset="190-200"
            type="drug_n" text="precocene I"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s2" text="This approach combines liquid chromatography mass spectrometry (LC MS) detection methods with multiple toxicity endpoints to enable identification of critical metabolic pathways for hepatotoxicity. "/>
    <sentence id="DDI-MedLine.d189.s3" text="The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. ">
        <entity id="DDI-MedLine.d189.s3.e0" charOffset="94-113"
            type="drug_n" text="1-aminobenzotriazole"/>
        <entity id="DDI-MedLine.d189.s3.e1" charOffset="116-118"
            type="drug_n" text="ABT"/>
        <pair id="DDI-MedLine.d189.s3.p0" e1="DDI-MedLine.d189.s3.e0"
            e2="DDI-MedLine.d189.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s4" text="The metabolite profile of precocene I in rat liver slices shares some features of the in vivo profile, but also had a major difference in that epoxide dihydrodiol hydrolysis products were not observed to a measurable extent. ">
        <entity id="DDI-MedLine.d189.s4.e0" charOffset="26-36"
            type="drug_n" text="precocene I"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s5" text="As examples of our liver slice metabolite identification procedure, a minor glutathione adduct and previously unreported 7-O-desmethyl and glucuronidated metabolites of precocene I are reported. ">
        <entity id="DDI-MedLine.d189.s5.e0" charOffset="169-179"
            type="drug_n" text="precocene I"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s6" text="Precocene I induced hepatocellular necrosis in a dose- and time-dependent manner. ">
        <entity id="DDI-MedLine.d189.s6.e0" charOffset="0-10"
            type="drug_n" text="Precocene I"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s7" text="ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ">
        <entity id="DDI-MedLine.d189.s7.e0" charOffset="0-2"
            type="drug_n" text="ABT"/>
        <entity id="DDI-MedLine.d189.s7.e1" charOffset="30-40"
            type="drug_n" text="precocene I"/>
        <pair id="DDI-MedLine.d189.s7.p0" e1="DDI-MedLine.d189.s7.e0"
            e2="DDI-MedLine.d189.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s8" text="Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ">
        <entity id="DDI-MedLine.d189.s8.e0" charOffset="67-77"
            type="drug_n" text="precocene I"/>
        <entity id="DDI-MedLine.d189.s8.e1" charOffset="104-118"
            type="drug" text="tranylcypromine"/>
        <pair id="DDI-MedLine.d189.s8.p0" e1="DDI-MedLine.d189.s8.e0"
            e2="DDI-MedLine.d189.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s9" text="With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ">
        <entity id="DDI-MedLine.d189.s9.e0" charOffset="71-73"
            type="drug_n" text="ABT"/>
        <entity id="DDI-MedLine.d189.s9.e1" charOffset="75-96"
            type="drug_n" text="diethyldithiocarbamate"/>
        <entity id="DDI-MedLine.d189.s9.e2" charOffset="98-112"
            type="drug" text="tranylcypromine"/>
        <entity id="DDI-MedLine.d189.s9.e3" charOffset="114-125"
            type="drug" text="ketoconazole"/>
        <pair id="DDI-MedLine.d189.s9.p0" e1="DDI-MedLine.d189.s9.e0"
            e2="DDI-MedLine.d189.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d189.s9.p1" e1="DDI-MedLine.d189.s9.e0"
            e2="DDI-MedLine.d189.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d189.s9.p2" e1="DDI-MedLine.d189.s9.e0"
            e2="DDI-MedLine.d189.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d189.s9.p3" e1="DDI-MedLine.d189.s9.e1"
            e2="DDI-MedLine.d189.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d189.s9.p4" e1="DDI-MedLine.d189.s9.e1"
            e2="DDI-MedLine.d189.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d189.s9.p5" e1="DDI-MedLine.d189.s9.e2"
            e2="DDI-MedLine.d189.s9.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s10" text="Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ">
        <entity id="DDI-MedLine.d189.s10.e0" charOffset="0-10"
            type="drug_n" text="Furafylline"/>
        <entity id="DDI-MedLine.d189.s10.e1" charOffset="16-29"
            type="drug_n" text="sulfaphenazole"/>
        <entity id="DDI-MedLine.d189.s10.e2" charOffset="52-60"
            type="drug" text="quinidine"/>
        <entity id="DDI-MedLine.d189.s10.e3" charOffset="82-92"
            type="drug_n" text="precocene I"/>
        <pair id="DDI-MedLine.d189.s10.p0" e1="DDI-MedLine.d189.s10.e0"
            e2="DDI-MedLine.d189.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d189.s10.p1" e1="DDI-MedLine.d189.s10.e0"
            e2="DDI-MedLine.d189.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d189.s10.p2" e1="DDI-MedLine.d189.s10.e0"
            e2="DDI-MedLine.d189.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d189.s10.p3" e1="DDI-MedLine.d189.s10.e1"
            e2="DDI-MedLine.d189.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d189.s10.p4" e1="DDI-MedLine.d189.s10.e1"
            e2="DDI-MedLine.d189.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d189.s10.p5" e1="DDI-MedLine.d189.s10.e2"
            e2="DDI-MedLine.d189.s10.e3" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s11" text="These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. ">
        <entity id="DDI-MedLine.d189.s11.e0" charOffset="103-113"
            type="drug_n" text="precocene I"/>
        <entity id="DDI-MedLine.d189.s11.e1" charOffset="165-175"
            type="drug_n" text="precocene I"/>
        <pair id="DDI-MedLine.d189.s11.p0" e1="DDI-MedLine.d189.s11.e0"
            e2="DDI-MedLine.d189.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d189.s12" text="However, these results provide an example of how small molecule manipulation of CYP activity in an in vitro model can be used to confirm metabolism-mediated toxicity."/>
    <sentence id="DDI-MedLine.d190.s0" text="Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.&#xd;&#xa;">
        <entity id="DDI-MedLine.d190.s0.e0" charOffset="83-86"
            type="drug_n" text="AAV2"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s1" text="To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).">
        <entity id="DDI-MedLine.d190.s1.e0" charOffset="145-168"
            type="drug_n" text="adeno-associated virus-2"/>
        <entity id="DDI-MedLine.d190.s1.e1" charOffset="171-174"
            type="drug_n" text="AAV2"/>
        <pair id="DDI-MedLine.d190.s1.p0" e1="DDI-MedLine.d190.s1.e0"
            e2="DDI-MedLine.d190.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s2" text="AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ">
        <entity id="DDI-MedLine.d190.s2.e0" charOffset="0-3"
            type="drug_n" text="AAV2"/>
        <entity id="DDI-MedLine.d190.s2.e1" charOffset="214-224"
            type="drug_n" text="collagenase"/>
        <entity id="DDI-MedLine.d190.s2.e2" charOffset="227-242"
            type="drug_n" text="hyaluronan lyase"/>
        <entity id="DDI-MedLine.d190.s2.e3" charOffset="245-258"
            type="drug_n" text="heparinase III"/>
        <entity id="DDI-MedLine.d190.s2.e4" charOffset="264-284"
            type="drug_n" text="chondroitin ABC lyase"/>
        <pair id="DDI-MedLine.d190.s2.p0" e1="DDI-MedLine.d190.s2.e0"
            e2="DDI-MedLine.d190.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p1" e1="DDI-MedLine.d190.s2.e0"
            e2="DDI-MedLine.d190.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p2" e1="DDI-MedLine.d190.s2.e0"
            e2="DDI-MedLine.d190.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p3" e1="DDI-MedLine.d190.s2.e0"
            e2="DDI-MedLine.d190.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p4" e1="DDI-MedLine.d190.s2.e1"
            e2="DDI-MedLine.d190.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p5" e1="DDI-MedLine.d190.s2.e1"
            e2="DDI-MedLine.d190.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p6" e1="DDI-MedLine.d190.s2.e1"
            e2="DDI-MedLine.d190.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p7" e1="DDI-MedLine.d190.s2.e2"
            e2="DDI-MedLine.d190.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p8" e1="DDI-MedLine.d190.s2.e2"
            e2="DDI-MedLine.d190.s2.e4" ddi="false"/>
        <pair id="DDI-MedLine.d190.s2.p9" e1="DDI-MedLine.d190.s2.e3"
            e2="DDI-MedLine.d190.s2.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s3" text="Two weeks later, retinal flatmounts were examined for GFP expression using confocal microscopy. "/>
    <sentence id="DDI-MedLine.d190.s4" text="Without the addition of enzymes, transduction was limited to occasional cells in the retinal ganglion cell layer. "/>
    <sentence id="DDI-MedLine.d190.s5" text="The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ">
        <entity id="DDI-MedLine.d190.s5.e0" charOffset="16-29"
            type="drug_n" text="heparinase III"/>
        <entity id="DDI-MedLine.d190.s5.e1" charOffset="34-54"
            type="drug_n" text="chondroitin ABC lyase"/>
        <pair id="DDI-MedLine.d190.s5.p0" e1="DDI-MedLine.d190.s5.e0"
            e2="DDI-MedLine.d190.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s6" text="Hyaluronan lyase had a limited effect and collagenase was ineffective. ">
        <entity id="DDI-MedLine.d190.s6.e0" charOffset="0-15"
            type="drug_n" text="Hyaluronan lyase"/>
        <entity id="DDI-MedLine.d190.s6.e1" charOffset="42-52"
            type="drug_n" text="collagenase"/>
        <pair id="DDI-MedLine.d190.s6.p0" e1="DDI-MedLine.d190.s6.e0"
            e2="DDI-MedLine.d190.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s7" text="Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. ">
        <entity id="DDI-MedLine.d190.s7.e0" charOffset="58-71"
            type="drug_n" text="heparinase III"/>
        <entity id="DDI-MedLine.d190.s7.e1" charOffset="77-97"
            type="drug_n" text="chondroitin ABC lyase"/>
        <pair id="DDI-MedLine.d190.s7.p0" e1="DDI-MedLine.d190.s7.e0"
            e2="DDI-MedLine.d190.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s8" text="AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ">
        <entity id="DDI-MedLine.d190.s8.e0" charOffset="0-3"
            type="drug_n" text="AAV2"/>
        <entity id="DDI-MedLine.d190.s8.e1" charOffset="66-79"
            type="drug_n" text="heparinase III"/>
        <entity id="DDI-MedLine.d190.s8.e2" charOffset="84-104"
            type="drug_n" text="chondroitin ABC lyase"/>
        <pair id="DDI-MedLine.d190.s8.p0" e1="DDI-MedLine.d190.s8.e0"
            e2="DDI-MedLine.d190.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d190.s8.p1" e1="DDI-MedLine.d190.s8.e0"
            e2="DDI-MedLine.d190.s8.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d190.s8.p2" e1="DDI-MedLine.d190.s8.e1"
            e2="DDI-MedLine.d190.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d190.s9" text="Improved transduction efficiency may allow intravitreal injection to become the preferred route for delivering gene therapy to both the inner and outer retina."/>
    <sentence id="DDI-MedLine.d199.s0" text="Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.&#xd;&#xa;">
        <entity id="DDI-MedLine.d199.s0.e0" charOffset="71-78"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d199.s0.e1" charOffset="84-91"
            type="drug" text="propofol"/>
        <pair id="DDI-MedLine.d199.s0.p0" e1="DDI-MedLine.d199.s0.e0"
            e2="DDI-MedLine.d199.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d199.s1" text="Emergence agitation (EA) can be a distressing side effect of pediatric anesthesia. "/>
    <sentence id="DDI-MedLine.d199.s2" text="We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ">
        <entity id="DDI-MedLine.d199.s2.e0" charOffset="95-102"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d199.s2.e1" charOffset="124-131"
            type="drug" text="propofol"/>
        <pair id="DDI-MedLine.d199.s2.p0" e1="DDI-MedLine.d199.s2.e0"
            e2="DDI-MedLine.d199.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d199.s3" text="EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ">
        <entity id="DDI-MedLine.d199.s3.e0" charOffset="61-68"
            type="drug" text="propofol"/>
        <entity id="DDI-MedLine.d199.s3.e1" charOffset="161-168"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d199.s3.e2" charOffset="183-190"
            type="drug" text="propofol"/>
        <pair id="DDI-MedLine.d199.s3.p0" e1="DDI-MedLine.d199.s3.e0"
            e2="DDI-MedLine.d199.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d199.s3.p1" e1="DDI-MedLine.d199.s3.e0"
            e2="DDI-MedLine.d199.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d199.s3.p2" e1="DDI-MedLine.d199.s3.e1"
            e2="DDI-MedLine.d199.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d199.s4" text="Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.">
        <entity id="DDI-MedLine.d199.s4.e0" charOffset="51-58"
            type="drug" text="ketamine"/>
        <entity id="DDI-MedLine.d199.s4.e1" charOffset="69-76"
            type="drug" text="propofol"/>
        <entity id="DDI-MedLine.d199.s4.e2" charOffset="156-163"
            type="drug" text="propofol"/>
        <pair id="DDI-MedLine.d199.s4.p0" e1="DDI-MedLine.d199.s4.e0"
            e2="DDI-MedLine.d199.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d199.s4.p1" e1="DDI-MedLine.d199.s4.e0"
            e2="DDI-MedLine.d199.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d199.s4.p2" e1="DDI-MedLine.d199.s4.e1"
            e2="DDI-MedLine.d199.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s0" text="Tamoxifen and CYP 2D6 inhibitors: caution.&#xd;&#xa;">
        <entity id="DDI-MedLine.d209.s0.e0" charOffset="0-8" type="drug" text="Tamoxifen"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s1" text="Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. ">
        <entity id="DDI-MedLine.d209.s1.e0" charOffset="0-8" type="drug" text="Tamoxifen"/>
        <entity id="DDI-MedLine.d209.s1.e1" charOffset="14-32"
            type="group" text="estrogen antagonist"/>
        <pair id="DDI-MedLine.d209.s1.p0" e1="DDI-MedLine.d209.s1.e0"
            e2="DDI-MedLine.d209.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s2" text="It is extensively transformed into its active metabolites by the cytochrome P450 enzyme system, especially into endoxifen by isoenzyme CYP 2D6. ">
        <entity id="DDI-MedLine.d209.s2.e0" charOffset="112-120"
            type="drug_n" text="endoxifen"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s3" text="Co-administration of tamoxifen with isoenzyme CYP 2D6 inhibitors reduces this metabolism. ">
        <entity id="DDI-MedLine.d209.s3.e0" charOffset="21-29"
            type="drug" text="tamoxifen"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s4" text="Selective serotonin reuptake inhibitor (SSRI) antidepressants inhibit isoenzyme CYP 2D6. ">
        <entity id="DDI-MedLine.d209.s4.e0" charOffset="0-60"
            type="group" text="Selective serotonin reuptake inhibitor (SSRI) antidepressants"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s5" text="Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ">
        <entity id="DDI-MedLine.d209.s5.e0" charOffset="0-9" type="drug" text="Paroxetine"/>
        <entity id="DDI-MedLine.d209.s5.e1" charOffset="15-24"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-MedLine.d209.s5.e2" charOffset="61-69"
            type="drug_n" text="endoxifen"/>
        <pair id="DDI-MedLine.d209.s5.p0" e1="DDI-MedLine.d209.s5.e0"
            e2="DDI-MedLine.d209.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d209.s5.p1" e1="DDI-MedLine.d209.s5.e0"
            e2="DDI-MedLine.d209.s5.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d209.s5.p2" e1="DDI-MedLine.d209.s5.e1"
            e2="DDI-MedLine.d209.s5.e2" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s6" text="Two epidemiological studies involving about 3700 women have shown a link between the use of SSRI antidepressants and an increased frequency of breast cancer recurrence. ">
        <entity id="DDI-MedLine.d209.s6.e0" charOffset="92-111"
            type="group" text="SSRI antidepressants"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s7" text="Other studies, with a lower level of evidence, were less convincing. "/>
    <sentence id="DDI-MedLine.d209.s8" text="Studies of other isoenzyme CYP 2D6 inhibitors showed no increase in the risk of breast cancer recurrence, but they lacked statistical power. "/>
    <sentence id="DDI-MedLine.d209.s9" text="It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ">
        <entity id="DDI-MedLine.d209.s9.e0" charOffset="85-93"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-MedLine.d209.s9.e1" charOffset="125-144"
            type="group" text="SSRI antidepressants"/>
        <entity id="DDI-MedLine.d209.s9.e2" charOffset="154-163"
            type="drug" text="paroxetine"/>
        <entity id="DDI-MedLine.d209.s9.e3" charOffset="169-178"
            type="drug" text="fluoxetine"/>
        <pair id="DDI-MedLine.d209.s9.p0" e1="DDI-MedLine.d209.s9.e0"
            e2="DDI-MedLine.d209.s9.e1" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d209.s9.p1" e1="DDI-MedLine.d209.s9.e0"
            e2="DDI-MedLine.d209.s9.e2" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d209.s9.p2" e1="DDI-MedLine.d209.s9.e0"
            e2="DDI-MedLine.d209.s9.e3" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d209.s9.p3" e1="DDI-MedLine.d209.s9.e1"
            e2="DDI-MedLine.d209.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d209.s9.p4" e1="DDI-MedLine.d209.s9.e1"
            e2="DDI-MedLine.d209.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d209.s9.p5" e1="DDI-MedLine.d209.s9.e2"
            e2="DDI-MedLine.d209.s9.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s10" text="Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. ">
        <entity id="DDI-MedLine.d209.s10.e0" charOffset="35-53"
            type="group" text="antidepressant drug"/>
        <entity id="DDI-MedLine.d209.s10.e1" charOffset="68-82"
            type="group" text="antidepressants"/>
        <pair id="DDI-MedLine.d209.s10.p0" e1="DDI-MedLine.d209.s10.e0"
            e2="DDI-MedLine.d209.s10.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d209.s11" text="If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.">
        <entity id="DDI-MedLine.d209.s11.e0" charOffset="24-37"
            type="group" text="antidepressant"/>
        <entity id="DDI-MedLine.d209.s11.e1" charOffset="95-103"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-MedLine.d209.s11.e2" charOffset="110-120"
            type="drug" text="anastrozole"/>
        <pair id="DDI-MedLine.d209.s11.p0" e1="DDI-MedLine.d209.s11.e0"
            e2="DDI-MedLine.d209.s11.e1" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d209.s11.p1" e1="DDI-MedLine.d209.s11.e0"
            e2="DDI-MedLine.d209.s11.e2" ddi="false"/>
        <pair id="DDI-MedLine.d209.s11.p2" e1="DDI-MedLine.d209.s11.e1"
            e2="DDI-MedLine.d209.s11.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s0" text="Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.&#xd;&#xa;">
        <entity id="DDI-MedLine.d184.s0.e0" charOffset="0-10"
            type="drug" text="Amphetamine"/>
        <entity id="DDI-MedLine.d184.s0.e1" charOffset="128-137"
            type="drug_n" text="quinpirole"/>
        <pair id="DDI-MedLine.d184.s0.p0" e1="DDI-MedLine.d184.s0.e0"
            e2="DDI-MedLine.d184.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s1" text="Neonatal quinpirole treatment has been shown to produce an increase in dopamine D2-like receptor sensitivity that persists throughout the subject's lifetime. ">
        <entity id="DDI-MedLine.d184.s1.e0" charOffset="9-18"
            type="drug_n" text="quinpirole"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s2" text="The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. ">
        <entity id="DDI-MedLine.d184.s2.e0" charOffset="53-62"
            type="drug_n" text="quinpirole"/>
        <entity id="DDI-MedLine.d184.s2.e1" charOffset="88-98"
            type="drug" text="amphetamine"/>
        <pair id="DDI-MedLine.d184.s2.p0" e1="DDI-MedLine.d184.s2.e0"
            e2="DDI-MedLine.d184.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s3" text="Sprague-Dawley rats were treated with quinpirole (1 mg/kg) or saline from postnatal days (P)1 to P11 and raised to adolescence. ">
        <entity id="DDI-MedLine.d184.s3.e0" charOffset="38-47"
            type="drug_n" text="quinpirole"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s4" text="For locomotor sensitization, subjects were given amphetamine (1 mg/kg) or saline every second day from P35 to P47 and were placed into a locomotor arena. ">
        <entity id="DDI-MedLine.d184.s4.e0" charOffset="49-59"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s5" text="In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ">
        <entity id="DDI-MedLine.d184.s5.e0" charOffset="25-34"
            type="drug_n" text="quinpirole"/>
        <entity id="DDI-MedLine.d184.s5.e1" charOffset="55-65"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d184.s5.e2" charOffset="105-114"
            type="drug_n" text="quinpirole"/>
        <entity id="DDI-MedLine.d184.s5.e3" charOffset="144-154"
            type="drug" text="amphetamine"/>
        <pair id="DDI-MedLine.d184.s5.p0" e1="DDI-MedLine.d184.s5.e0"
            e2="DDI-MedLine.d184.s5.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d184.s5.p1" e1="DDI-MedLine.d184.s5.e0"
            e2="DDI-MedLine.d184.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d184.s5.p2" e1="DDI-MedLine.d184.s5.e0"
            e2="DDI-MedLine.d184.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d184.s5.p3" e1="DDI-MedLine.d184.s5.e1"
            e2="DDI-MedLine.d184.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d184.s5.p4" e1="DDI-MedLine.d184.s5.e1"
            e2="DDI-MedLine.d184.s5.e3" ddi="false"/>
        <pair id="DDI-MedLine.d184.s5.p5" e1="DDI-MedLine.d184.s5.e2"
            e2="DDI-MedLine.d184.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s6" text="Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. ">
        <entity id="DDI-MedLine.d184.s6.e0" charOffset="40-50"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d184.s6.e1" charOffset="136-145"
            type="drug_n" text="quinpirole"/>
        <pair id="DDI-MedLine.d184.s6.p0" e1="DDI-MedLine.d184.s6.e0"
            e2="DDI-MedLine.d184.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s7" text="For conditioned place preference, subjects were conditioned for 8 consecutive days (P32-39) with amphetamine (1 mg/kg) or saline and a drug-free preference test was conducted at P40. ">
        <entity id="DDI-MedLine.d184.s7.e0" charOffset="97-107"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s8" text="Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ">
        <entity id="DDI-MedLine.d184.s8.e0" charOffset="27-36"
            type="drug_n" text="quinpirole"/>
        <entity id="DDI-MedLine.d184.s8.e1" charOffset="65-75"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d184.s8.e2" charOffset="106-115"
            type="drug_n" text="quinpirole"/>
        <entity id="DDI-MedLine.d184.s8.e3" charOffset="148-158"
            type="drug" text="amphetamine"/>
        <entity id="DDI-MedLine.d184.s8.e4" charOffset="203-213"
            type="drug" text="amphetamine"/>
        <pair id="DDI-MedLine.d184.s8.p0" e1="DDI-MedLine.d184.s8.e0"
            e2="DDI-MedLine.d184.s8.e1" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p1" e1="DDI-MedLine.d184.s8.e0"
            e2="DDI-MedLine.d184.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p2" e1="DDI-MedLine.d184.s8.e0"
            e2="DDI-MedLine.d184.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p3" e1="DDI-MedLine.d184.s8.e0"
            e2="DDI-MedLine.d184.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p4" e1="DDI-MedLine.d184.s8.e1"
            e2="DDI-MedLine.d184.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p5" e1="DDI-MedLine.d184.s8.e1"
            e2="DDI-MedLine.d184.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p6" e1="DDI-MedLine.d184.s8.e1"
            e2="DDI-MedLine.d184.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p7" e1="DDI-MedLine.d184.s8.e2"
            e2="DDI-MedLine.d184.s8.e3" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p8" e1="DDI-MedLine.d184.s8.e2"
            e2="DDI-MedLine.d184.s8.e4" ddi="false"/>
        <pair id="DDI-MedLine.d184.s8.p9" e1="DDI-MedLine.d184.s8.e3"
            e2="DDI-MedLine.d184.s8.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d184.s9" text="Increased D   -like receptor sensitivity appears to have enhanced the behavioral effects of amphetamine, but these effects were more prevalent in adolescent female rats compared with male rats.">
        <entity id="DDI-MedLine.d184.s9.e0" charOffset="92-102"
            type="drug" text="amphetamine"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s0" text="In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.&#xd;&#xa;">
        <entity id="DDI-MedLine.d213.s0.e0" charOffset="49-60"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d213.s0.e1" charOffset="87-96"
            type="drug" text="tacrolimus"/>
        <pair id="DDI-MedLine.d213.s0.p0" e1="DDI-MedLine.d213.s0.e0"
            e2="DDI-MedLine.d213.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s1" text="In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. ">
        <entity id="DDI-MedLine.d213.s1.e0" charOffset="33-44"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d213.s1.e1" charOffset="50-59"
            type="drug" text="tacrolimus"/>
        <pair id="DDI-MedLine.d213.s1.p0" e1="DDI-MedLine.d213.s1.e0"
            e2="DDI-MedLine.d213.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s2" text="In the current study in renal allograft recipients, we used intravenously and orally administered midazolam as a drug probe to assess whether the study drugs at doses that are generally used in clinical practice have differential effects on in vivo hepatic and first-pass CYP3A activities. ">
        <entity id="DDI-MedLine.d213.s2.e0" charOffset="98-106"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s3" text="Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ">
        <entity id="DDI-MedLine.d213.s3.e0" charOffset="27-35"
            type="drug" text="midazolam"/>
        <entity id="DDI-MedLine.d213.s3.e1" charOffset="181-192"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d213.s3.e2" charOffset="236-245"
            type="drug" text="tacrolimus"/>
        <pair id="DDI-MedLine.d213.s3.p0" e1="DDI-MedLine.d213.s3.e0"
            e2="DDI-MedLine.d213.s3.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d213.s3.p1" e1="DDI-MedLine.d213.s3.e0"
            e2="DDI-MedLine.d213.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d213.s3.p2" e1="DDI-MedLine.d213.s3.e1"
            e2="DDI-MedLine.d213.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s4" text="The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ">
        <entity id="DDI-MedLine.d213.s4.e0" charOffset="21-29"
            type="drug" text="midazolam"/>
        <entity id="DDI-MedLine.d213.s4.e1" charOffset="95-104"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-MedLine.d213.s4.e2" charOffset="168-188"
            type="group" text="calcineurin inhibitor"/>
        <pair id="DDI-MedLine.d213.s4.p0" e1="DDI-MedLine.d213.s4.e0"
            e2="DDI-MedLine.d213.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d213.s4.p1" e1="DDI-MedLine.d213.s4.e0"
            e2="DDI-MedLine.d213.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d213.s4.p2" e1="DDI-MedLine.d213.s4.e1"
            e2="DDI-MedLine.d213.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s5" text="This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ">
        <entity id="DDI-MedLine.d213.s5.e0" charOffset="112-123"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-MedLine.d213.s5.e1" charOffset="149-158"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-MedLine.d213.s5.e2" charOffset="228-239"
            type="drug" text="cyclosporine"/>
        <pair id="DDI-MedLine.d213.s5.p0" e1="DDI-MedLine.d213.s5.e0"
            e2="DDI-MedLine.d213.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d213.s5.p1" e1="DDI-MedLine.d213.s5.e0"
            e2="DDI-MedLine.d213.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d213.s5.p2" e1="DDI-MedLine.d213.s5.e1"
            e2="DDI-MedLine.d213.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d213.s6" text="This observation has important implications in the context of drug-drug interactions in transplant recipients."/>
    <sentence id="DDI-MedLine.d166.s0" text="Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.&#xd;&#xa;">
        <entity id="DDI-MedLine.d166.s0.e0" charOffset="40-49"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s0.e1" charOffset="83-93"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s0.p0" e1="DDI-MedLine.d166.s0.e0"
            e2="DDI-MedLine.d166.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s1" text="Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. ">
        <entity id="DDI-MedLine.d166.s1.e0" charOffset="75-88"
            type="drug" text="erythropoietin"/>
        <entity id="DDI-MedLine.d166.s1.e1" charOffset="91-93"
            type="drug" text="EPO"/>
        <pair id="DDI-MedLine.d166.s1.p0" e1="DDI-MedLine.d166.s1.e0"
            e2="DDI-MedLine.d166.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s2" text="Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ">
        <entity id="DDI-MedLine.d166.s2.e0" charOffset="23-32"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s2.e1" charOffset="118-128"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s2.p0" e1="DDI-MedLine.d166.s2.e0"
            e2="DDI-MedLine.d166.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s3" text="METHODS AND AIMS: We conducted a retrospective cohort study of 40 end-stage renal disease (ESRD) patients (age: 55    14; mean    SD; 21:male) who had at least 12 months of cinacalcet therapy. ">
        <entity id="DDI-MedLine.d166.s3.e0" charOffset="173-182"
            type="drug" text="cinacalcet"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s4" text="The distribution of renal replacement therapies were: 14 peritoneal dialysis, 18 conventional hemodialysis and 8 nocturnal hemodialysis. "/>
    <sentence id="DDI-MedLine.d166.s5" text="Standard dialysis related biochemical indices and medications used were recorded. "/>
    <sentence id="DDI-MedLine.d166.s6" text="The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ">
        <entity id="DDI-MedLine.d166.s6.e0" charOffset="70-80"
            type="drug" text="darbepoetin"/>
        <entity id="DDI-MedLine.d166.s6.e1" charOffset="127-136"
            type="drug" text="cinacalcet"/>
        <pair id="DDI-MedLine.d166.s6.p0" e1="DDI-MedLine.d166.s6.e0"
            e2="DDI-MedLine.d166.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s7" text="Our secondary objective was to determine if there was a relationship between the changes in PTH and darbepoetin requirement.">
        <entity id="DDI-MedLine.d166.s7.e0" charOffset="100-110"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s8" text="Overall, PTH levels decreased from 197.5 (151.8; 249.2) to 66.1 (41.2; 136.5) (median (25th;75th percentile)) pmol/l; "/>
    <sentence id="DDI-MedLine.d166.s9" text="p &amp;lt; "/>
    <sentence id="DDI-MedLine.d166.s10" text="0.001. "/>
    <sentence id="DDI-MedLine.d166.s11" text="Cinacalcet dose increased from 30.0   6 to 63   25 mg/day, p &lt;">
        <entity id="DDI-MedLine.d166.s11.e0" charOffset="0-9"
            type="drug" text="Cinacalcet"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s12" text="0.05. "/>
    <sentence id="DDI-MedLine.d166.s13" text="Hemoglobin remained unchanged (116   13 to 116   13 g/l), while darbepoetin requirement decreased from 40 (20; 60) to 24 (19; 59)   g/week, p = 0.02.">
        <entity id="DDI-MedLine.d166.s13.e0" charOffset="64-74"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s14" text="The remainder of the dialysis-related biochemistry (electrolytes, calcium, phosphate, iron status) and vitamin D use remained unchanged. "/>
    <sentence id="DDI-MedLine.d166.s15" text="A reduction in PTH level of greater than 30% was experienced by 82.5% (33/40) of our cohort. "/>
    <sentence id="DDI-MedLine.d166.s16" text="Among the responders, the fall in PTH and reduction darbepoetin requirement were related (R = -0.48, p = 0.004). ">
        <entity id="DDI-MedLine.d166.s16.e0" charOffset="52-62"
            type="drug" text="darbepoetin"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s17" text="Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ">
        <entity id="DDI-MedLine.d166.s17.e0" charOffset="20-29"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-MedLine.d166.s17.e1" charOffset="64-74"
            type="drug" text="darbepoetin"/>
        <pair id="DDI-MedLine.d166.s17.p0" e1="DDI-MedLine.d166.s17.e0"
            e2="DDI-MedLine.d166.s17.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d166.s18" text="The interface between bone and bone marrow in uremia represents a critical step in red blood cell production which merits further investigation."/>
    <sentence id="DDI-MedLine.d217.s0" text="Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.&#xd;&#xa;">
        <entity id="DDI-MedLine.d217.s0.e0" charOffset="15-23"
            type="drug" text="celecoxib"/>
        <entity id="DDI-MedLine.d217.s0.e1" charOffset="40-56"
            type="group" text="anti-cancer drugs"/>
        <pair id="DDI-MedLine.d217.s0.p0" e1="DDI-MedLine.d217.s0.e0"
            e2="DDI-MedLine.d217.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s1" text="Celecoxib, an inhibitor of cyclooxygenase-2, is being investigated for enhancement of chemotherapy efficacy in cancer clinical trials. ">
        <entity id="DDI-MedLine.d217.s1.e0" charOffset="0-8" type="drug" text="Celecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s2" text="This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. ">
        <entity id="DDI-MedLine.d217.s2.e0" charOffset="39-65"
            type="group" text="cyclooxygenase-2 inhibitors"/>
        <entity id="DDI-MedLine.d217.s2.e1" charOffset="120-142"
            type="group" text="chemotherapeutic agents"/>
        <pair id="DDI-MedLine.d217.s2.p0" e1="DDI-MedLine.d217.s2.e0"
            e2="DDI-MedLine.d217.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s3" text="The effect of the drug's mechanism of action and sequence of administration are also investigated. "/>
    <sentence id="DDI-MedLine.d217.s4" text="The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.">
        <entity id="DDI-MedLine.d217.s4.e0" charOffset="130-133"
            type="drug" text="5-FU"/>
        <entity id="DDI-MedLine.d217.s4.e1" charOffset="136-144"
            type="drug" text="cisplatin"/>
        <entity id="DDI-MedLine.d217.s4.e2" charOffset="147-157"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-MedLine.d217.s4.e3" charOffset="163-171"
            type="drug" text="etoposide"/>
        <entity id="DDI-MedLine.d217.s4.e4" charOffset="175-183"
            type="drug" text="celecoxib"/>
        <pair id="DDI-MedLine.d217.s4.p0" e1="DDI-MedLine.d217.s4.e0"
            e2="DDI-MedLine.d217.s4.e1" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p1" e1="DDI-MedLine.d217.s4.e0"
            e2="DDI-MedLine.d217.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p2" e1="DDI-MedLine.d217.s4.e0"
            e2="DDI-MedLine.d217.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p3" e1="DDI-MedLine.d217.s4.e0"
            e2="DDI-MedLine.d217.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p4" e1="DDI-MedLine.d217.s4.e1"
            e2="DDI-MedLine.d217.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p5" e1="DDI-MedLine.d217.s4.e1"
            e2="DDI-MedLine.d217.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p6" e1="DDI-MedLine.d217.s4.e1"
            e2="DDI-MedLine.d217.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p7" e1="DDI-MedLine.d217.s4.e2"
            e2="DDI-MedLine.d217.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p8" e1="DDI-MedLine.d217.s4.e2"
            e2="DDI-MedLine.d217.s4.e4" ddi="false"/>
        <pair id="DDI-MedLine.d217.s4.p9" e1="DDI-MedLine.d217.s4.e3"
            e2="DDI-MedLine.d217.s4.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s5" text="We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ">
        <entity id="DDI-MedLine.d217.s5.e0" charOffset="28-36"
            type="drug" text="celecoxib"/>
        <entity id="DDI-MedLine.d217.s5.e1" charOffset="136-144"
            type="drug" text="celecoxib"/>
        <entity id="DDI-MedLine.d217.s5.e2" charOffset="150-160"
            type="drug" text="doxorubicin"/>
        <pair id="DDI-MedLine.d217.s5.p0" e1="DDI-MedLine.d217.s5.e0"
            e2="DDI-MedLine.d217.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d217.s5.p1" e1="DDI-MedLine.d217.s5.e0"
            e2="DDI-MedLine.d217.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d217.s5.p2" e1="DDI-MedLine.d217.s5.e1"
            e2="DDI-MedLine.d217.s5.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s6" text="Celecoxib with the other three drugs in the remaining four cell lines resulted in variable interactions. ">
        <entity id="DDI-MedLine.d217.s6.e0" charOffset="0-8" type="drug" text="Celecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s7" text="Mechanistic investigations revealed that celecoxib exerts different molecular effects in different cells. ">
        <entity id="DDI-MedLine.d217.s7.e0" charOffset="41-49"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s8" text="In some lines, it abrogates the drug-induced G2/M arrest enhancing pre-mature entry into mitosis with damaged DNA thus increasing apoptosis and resulting in synergism. "/>
    <sentence id="DDI-MedLine.d217.s9" text="In other cells, it enhances drug-induced G2/M arrest allowing time to repair drug-induced DNA damage before entry into mitosis and decreasing cell death resulting in antagonism. "/>
    <sentence id="DDI-MedLine.d217.s10" text="In some synergistic combinations, celecoxib-induced abrogation of G2/M arrest was not associated with apoptosis but permanent arrest in G1 phase. "/>
    <sentence id="DDI-MedLine.d217.s11" text="These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. ">
        <entity id="DDI-MedLine.d217.s11.e0" charOffset="51-59"
            type="drug" text="celecoxib"/>
        <entity id="DDI-MedLine.d217.s11.e1" charOffset="121-131"
            type="drug" text="doxorubicin"/>
        <pair id="DDI-MedLine.d217.s11.p0" e1="DDI-MedLine.d217.s11.e0"
            e2="DDI-MedLine.d217.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d217.s12" text="Moreover, combination of celecoxib with other drugs should be tailored to the tumor type, drug and administration schedule.">
        <entity id="DDI-MedLine.d217.s12.e0" charOffset="25-33"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s0" text="[Interaction between clopidogrel and proton pump inhibitors].&#xd;&#xa;">
        <entity id="DDI-MedLine.d143.s0.e0" charOffset="21-31"
            type="drug" text="clopidogrel"/>
        <entity id="DDI-MedLine.d143.s0.e1" charOffset="37-58"
            type="group" text="proton pump inhibitors"/>
        <pair id="DDI-MedLine.d143.s0.p0" e1="DDI-MedLine.d143.s0.e0"
            e2="DDI-MedLine.d143.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s1" text="The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. ">
        <entity id="DDI-MedLine.d143.s1.e0" charOffset="29-50"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-MedLine.d143.s1.e1" charOffset="56-66"
            type="drug" text="clopidogrel"/>
        <pair id="DDI-MedLine.d143.s1.p0" e1="DDI-MedLine.d143.s1.e0"
            e2="DDI-MedLine.d143.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s2" text="Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. ">
        <entity id="DDI-MedLine.d143.s2.e0" charOffset="46-67"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-MedLine.d143.s2.e1" charOffset="119-129"
            type="drug" text="clopidogrel"/>
        <pair id="DDI-MedLine.d143.s2.p0" e1="DDI-MedLine.d143.s2.e0"
            e2="DDI-MedLine.d143.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s3" text="Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ">
        <entity id="DDI-MedLine.d143.s3.e0" charOffset="19-28"
            type="drug" text="omeprazole"/>
        <entity id="DDI-MedLine.d143.s3.e1" charOffset="34-44"
            type="drug" text="clopidogrel"/>
        <entity id="DDI-MedLine.d143.s3.e2" charOffset="203-212"
            type="drug" text="omeprazole"/>
        <pair id="DDI-MedLine.d143.s3.p0" e1="DDI-MedLine.d143.s3.e0"
            e2="DDI-MedLine.d143.s3.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d143.s3.p1" e1="DDI-MedLine.d143.s3.e0"
            e2="DDI-MedLine.d143.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d143.s3.p2" e1="DDI-MedLine.d143.s3.e1"
            e2="DDI-MedLine.d143.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s4" text="Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ">
        <entity id="DDI-MedLine.d143.s4.e0" charOffset="0-11"
            type="drug" text="Pantoprazole"/>
        <entity id="DDI-MedLine.d143.s4.e1" charOffset="41-51"
            type="drug" text="clopidogrel"/>
        <pair id="DDI-MedLine.d143.s4.p0" e1="DDI-MedLine.d143.s4.e0"
            e2="DDI-MedLine.d143.s4.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s5" text="The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. ">
        <entity id="DDI-MedLine.d143.s5.e0" charOffset="27-48"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-MedLine.d143.s5.e1" charOffset="80-90"
            type="drug" text="clopidogrel"/>
        <pair id="DDI-MedLine.d143.s5.p0" e1="DDI-MedLine.d143.s5.e0"
            e2="DDI-MedLine.d143.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s6" text="Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ">
        <entity id="DDI-MedLine.d143.s6.e0" charOffset="50-60"
            type="drug" text="clopidogrel"/>
        <entity id="DDI-MedLine.d143.s6.e1" charOffset="89-98"
            type="drug" text="omeprazole"/>
        <entity id="DDI-MedLine.d143.s6.e2" charOffset="104-115"
            type="drug" text="esomeprazole"/>
        <pair id="DDI-MedLine.d143.s6.p0" e1="DDI-MedLine.d143.s6.e0"
            e2="DDI-MedLine.d143.s6.e1" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d143.s6.p1" e1="DDI-MedLine.d143.s6.e0"
            e2="DDI-MedLine.d143.s6.e2" ddi="true" type="advise"/>
        <pair id="DDI-MedLine.d143.s6.p2" e1="DDI-MedLine.d143.s6.e1"
            e2="DDI-MedLine.d143.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d143.s7" text="To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.">
        <entity id="DDI-MedLine.d143.s7.e0" charOffset="97-118"
            type="group" text="proton pump inhibitors"/>
        <entity id="DDI-MedLine.d143.s7.e1" charOffset="124-134"
            type="drug" text="clopidogrel"/>
        <pair id="DDI-MedLine.d143.s7.p0" e1="DDI-MedLine.d143.s7.e0"
            e2="DDI-MedLine.d143.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s0" text="In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.&#xd;&#xa;">
        <entity id="DDI-MedLine.d163.s0.e0" charOffset="21-31"
            type="drug" text="minocycline"/>
        <entity id="DDI-MedLine.d163.s0.e1" charOffset="47-56"
            type="drug" text="fosfomycin"/>
        <entity id="DDI-MedLine.d163.s0.e2" charOffset="87-97"
            type="drug" text="methicillin"/>
        <pair id="DDI-MedLine.d163.s0.p0" e1="DDI-MedLine.d163.s0.e0"
            e2="DDI-MedLine.d163.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d163.s0.p1" e1="DDI-MedLine.d163.s0.e0"
            e2="DDI-MedLine.d163.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d163.s0.p2" e1="DDI-MedLine.d163.s0.e1"
            e2="DDI-MedLine.d163.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s1" text="This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ">
        <entity id="DDI-MedLine.d163.s1.e0" charOffset="54-64"
            type="drug" text="minocycline"/>
        <entity id="DDI-MedLine.d163.s1.e1" charOffset="80-89"
            type="drug" text="fosfomycin"/>
        <entity id="DDI-MedLine.d163.s1.e2" charOffset="111-121"
            type="drug" text="methicillin"/>
        <pair id="DDI-MedLine.d163.s1.p0" e1="DDI-MedLine.d163.s1.e0"
            e2="DDI-MedLine.d163.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d163.s1.p1" e1="DDI-MedLine.d163.s1.e0"
            e2="DDI-MedLine.d163.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d163.s1.p2" e1="DDI-MedLine.d163.s1.e1"
            e2="DDI-MedLine.d163.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s2" text="A total of 87 clinical isolates of MRSA collected from three Chinese hospitals were included in the study. "/>
    <sentence id="DDI-MedLine.d163.s3" text="The checkerboard method with determination of the fractional IC index (FICI) was used to determine whether antibiotic combinations act synergistically against these isolates. ">
        <entity id="DDI-MedLine.d163.s3.e0" charOffset="107-116"
            type="group" text="antibiotic"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s4" text="The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. ">
        <entity id="DDI-MedLine.d163.s4.e0" charOffset="31-41"
            type="drug" text="minocycline"/>
        <entity id="DDI-MedLine.d163.s4.e1" charOffset="47-56"
            type="drug" text="fosfomycin"/>
        <pair id="DDI-MedLine.d163.s4.p0" e1="DDI-MedLine.d163.s4.e0"
            e2="DDI-MedLine.d163.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s5" text="The results demonstrated the following interactions: 76 isolates (87.4%) showed synergistic interactions (FICI   0.5) and 11 isolates (12.6%) showed indifferent interactions (0.5&amp;lt;FICI&amp;lt;4). "/>
    <sentence id="DDI-MedLine.d163.s6" text="No antagonistic interactions (FICI   4) were observed. "/>
    <sentence id="DDI-MedLine.d163.s7" text="The combination of minocycline and fosfomycin can be synergistic against MRSA. ">
        <entity id="DDI-MedLine.d163.s7.e0" charOffset="19-29"
            type="drug" text="minocycline"/>
        <entity id="DDI-MedLine.d163.s7.e1" charOffset="35-44"
            type="drug" text="fosfomycin"/>
        <pair id="DDI-MedLine.d163.s7.p0" e1="DDI-MedLine.d163.s7.e0"
            e2="DDI-MedLine.d163.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d163.s8" text="Further studies are required to determine the potential clinical role of this combination regimen as a therapeutic alternative for certain types of MRSA infections."/>
    <sentence id="DDI-MedLine.d181.s0" text="Drug interaction of levothyroxine with infant colic drops.&#xd;&#xa;">
        <entity id="DDI-MedLine.d181.s0.e0" charOffset="20-32"
            type="drug" text="levothyroxine"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s1" text="Infacol (Forest Laboratories UK, Kent, UK) is a widely available over-the-counter preparation used to relieve colic symptoms in neonates and infants. ">
        <entity id="DDI-MedLine.d181.s1.e0" charOffset="0-6"
            type="brand" text="Infacol"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s2" text="The active ingredient is simeticone. ">
        <entity id="DDI-MedLine.d181.s2.e0" charOffset="25-34"
            type="drug" text="simeticone"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s3" text="No drug interactions with simeticone are documented in the current summary of product characteristics. ">
        <entity id="DDI-MedLine.d181.s3.e0" charOffset="26-35"
            type="drug" text="simeticone"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s4" text="The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ">
        <entity id="DDI-MedLine.d181.s4.e0" charOffset="85-97"
            type="drug" text="levothyroxine"/>
        <entity id="DDI-MedLine.d181.s4.e1" charOffset="148-157"
            type="drug" text="simeticone"/>
        <pair id="DDI-MedLine.d181.s4.p0" e1="DDI-MedLine.d181.s4.e0"
            e2="DDI-MedLine.d181.s4.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s5" text="Despite adequate levothyroxine dosage, thyroid stimulating hormone (TSH) was high, suggesting undertreatment. ">
        <entity id="DDI-MedLine.d181.s5.e0" charOffset="17-29"
            type="drug" text="levothyroxine"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s6" text="Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. ">
        <entity id="DDI-MedLine.d181.s6.e0" charOffset="42-48"
            type="brand" text="Infacol"/>
        <entity id="DDI-MedLine.d181.s6.e1" charOffset="78-90"
            type="drug" text="levothyroxine"/>
        <pair id="DDI-MedLine.d181.s6.p0" e1="DDI-MedLine.d181.s6.e0"
            e2="DDI-MedLine.d181.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s7" text="The colic drops were immediately discontinued and TSH promptly normalised with a reduction in thyroxine requirement to an age appropriate dosage. "/>
    <sentence id="DDI-MedLine.d181.s8" text="Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. ">
        <entity id="DDI-MedLine.d181.s8.e0" charOffset="20-28"
            type="drug" text="thyroxine"/>
        <entity id="DDI-MedLine.d181.s8.e1" charOffset="35-44"
            type="drug" text="simeticone"/>
        <pair id="DDI-MedLine.d181.s8.p0" e1="DDI-MedLine.d181.s8.e0"
            e2="DDI-MedLine.d181.s8.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d181.s9" text="Clinicians and parents need to be aware of this interaction to avoid unnecessary undertreatment and prevent potential long-term neurological sequelae."/>
    <sentence id="DDI-MedLine.d169.s0" text="Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.">
        <entity id="DDI-MedLine.d169.s0.e0" charOffset="0-6" type="drug" text="Calcium"/>
        <entity id="DDI-MedLine.d169.s0.e1" charOffset="59-65;75-78"
            type="drug" text="nonheme iron"/>
        <entity id="DDI-MedLine.d169.s0.e2" charOffset="70-78"
            type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s0.p0" e1="DDI-MedLine.d169.s0.e0"
            e2="DDI-MedLine.d169.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d169.s0.p1" e1="DDI-MedLine.d169.s0.e0"
            e2="DDI-MedLine.d169.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d169.s0.p2" e1="DDI-MedLine.d169.s0.e1"
            e2="DDI-MedLine.d169.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s1" text="Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ">
        <entity id="DDI-MedLine.d169.s1.e0" charOffset="0-6" type="drug" text="Calcium"/>
        <entity id="DDI-MedLine.d169.s1.e1" charOffset="83-89;100-103"
            type="drug" text="nonheme iron"/>
        <entity id="DDI-MedLine.d169.s1.e2" charOffset="95-103"
            type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s1.p0" e1="DDI-MedLine.d169.s1.e0"
            e2="DDI-MedLine.d169.s1.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d169.s1.p1" e1="DDI-MedLine.d169.s1.e0"
            e2="DDI-MedLine.d169.s1.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d169.s1.p2" e1="DDI-MedLine.d169.s1.e1"
            e2="DDI-MedLine.d169.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s2" text="However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ">
        <entity id="DDI-MedLine.d169.s2.e0" charOffset="28-34"
            type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s2.e1" charOffset="46-49"
            type="drug" text="iron"/>
        <entity id="DDI-MedLine.d169.s2.e2" charOffset="123-129"
            type="drug" text="calcium"/>
        <pair id="DDI-MedLine.d169.s2.p0" e1="DDI-MedLine.d169.s2.e0"
            e2="DDI-MedLine.d169.s2.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d169.s2.p1" e1="DDI-MedLine.d169.s2.e0"
            e2="DDI-MedLine.d169.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d169.s2.p2" e1="DDI-MedLine.d169.s2.e1"
            e2="DDI-MedLine.d169.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s3" text="Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ">
        <entity id="DDI-MedLine.d169.s3.e0" charOffset="52-58"
            type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s3.e1" charOffset="77-83;94-97"
            type="drug" text="nonheme iron"/>
        <entity id="DDI-MedLine.d169.s3.e2" charOffset="89-97"
            type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s3.p0" e1="DDI-MedLine.d169.s3.e0"
            e2="DDI-MedLine.d169.s3.e1" ddi="false"/>
        <pair id="DDI-MedLine.d169.s3.p1" e1="DDI-MedLine.d169.s3.e0"
            e2="DDI-MedLine.d169.s3.e2" ddi="false"/>
        <pair id="DDI-MedLine.d169.s3.p2" e1="DDI-MedLine.d169.s3.e1"
            e2="DDI-MedLine.d169.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s4" text="Fifty-four healthy, nonpregnant women were selected to participate in 4 iron absorption studies using iron radioactive tracers. ">
        <entity id="DDI-MedLine.d169.s4.e0" charOffset="72-75"
            type="drug" text="iron"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s5" text="We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ">
        <entity id="DDI-MedLine.d169.s5.e0" charOffset="28-34"
            type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s5.e1" charOffset="88-99"
            type="drug" text="nonheme iron"/>
        <entity id="DDI-MedLine.d169.s5.e2" charOffset="105-119"
            type="drug" text="ferrous sulfate"/>
        <pair id="DDI-MedLine.d169.s5.p0" e1="DDI-MedLine.d169.s5.e0"
            e2="DDI-MedLine.d169.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d169.s5.p1" e1="DDI-MedLine.d169.s5.e0"
            e2="DDI-MedLine.d169.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d169.s5.p2" e1="DDI-MedLine.d169.s5.e1"
            e2="DDI-MedLine.d169.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s6" text="We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. ">
        <entity id="DDI-MedLine.d169.s6.e0" charOffset="33-39"
            type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s6.e1" charOffset="92-100"
            type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s6.p0" e1="DDI-MedLine.d169.s6.e0"
            e2="DDI-MedLine.d169.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s7" text="Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ">
        <entity id="DDI-MedLine.d169.s7.e0" charOffset="0-6" type="drug" text="Calcium"/>
        <entity id="DDI-MedLine.d169.s7.e1" charOffset="28-43"
            type="drug" text="calcium chloride"/>
        <entity id="DDI-MedLine.d169.s7.e2" charOffset="64-71"
            type="group" text="minerals"/>
        <pair id="DDI-MedLine.d169.s7.p0" e1="DDI-MedLine.d169.s7.e0"
            e2="DDI-MedLine.d169.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d169.s7.p1" e1="DDI-MedLine.d169.s7.e0"
            e2="DDI-MedLine.d169.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d169.s7.p2" e1="DDI-MedLine.d169.s7.e1"
            e2="DDI-MedLine.d169.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s8" text="Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.">
        <entity id="DDI-MedLine.d169.s8.e0" charOffset="0-6" type="drug" text="Calcium"/>
        <entity id="DDI-MedLine.d169.s8.e1" charOffset="35-46"
            type="drug" text="nonheme iron"/>
        <pair id="DDI-MedLine.d169.s8.p0" e1="DDI-MedLine.d169.s8.e0"
            e2="DDI-MedLine.d169.s8.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s9" text="A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ">
        <entity id="DDI-MedLine.d169.s9.e0" charOffset="2-8" type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s9.e1" charOffset="55-63"
            type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s9.p0" e1="DDI-MedLine.d169.s9.e0"
            e2="DDI-MedLine.d169.s9.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s10" text="In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ">
        <entity id="DDI-MedLine.d169.s10.e0" charOffset="53-59"
            type="drug" text="calcium"/>
        <entity id="DDI-MedLine.d169.s10.e1"
            charOffset="117-123;157-160" type="drug" text="nonheme iron"/>
        <entity id="DDI-MedLine.d169.s10.e2"
            charOffset="142-145;157-160" type="drug" text="heme iron"/>
        <pair id="DDI-MedLine.d169.s10.p0" e1="DDI-MedLine.d169.s10.e0"
            e2="DDI-MedLine.d169.s10.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d169.s10.p1" e1="DDI-MedLine.d169.s10.e0"
            e2="DDI-MedLine.d169.s10.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d169.s10.p2" e1="DDI-MedLine.d169.s10.e1"
            e2="DDI-MedLine.d169.s10.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d169.s11" text="This effect was observed at doses higher than previously reported from single-meal studies, starting at ~800 mg of calcium.">
        <entity id="DDI-MedLine.d169.s11.e0" charOffset="115-121"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s0" text="Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.">
        <entity id="DDI-MedLine.d179.s0.e0" charOffset="32-40"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s0.e1" charOffset="46-54"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s0.p0" e1="DDI-MedLine.d179.s0.e0"
            e2="DDI-MedLine.d179.s0.e1" ddi="true" type="int"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s1" text="Previous studies have demonstrated that sunitinib has the anti-tumor activity in human non-small cell lung cancer (NSCLC). ">
        <entity id="DDI-MedLine.d179.s1.e0" charOffset="40-48"
            type="drug" text="sunitinib"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s2" text="This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.">
        <entity id="DDI-MedLine.d179.s2.e0" charOffset="66-74"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s2.e1" charOffset="131-139"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s2.e2" charOffset="145-153"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s2.p0" e1="DDI-MedLine.d179.s2.e0"
            e2="DDI-MedLine.d179.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d179.s2.p1" e1="DDI-MedLine.d179.s2.e0"
            e2="DDI-MedLine.d179.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d179.s2.p2" e1="DDI-MedLine.d179.s2.e1"
            e2="DDI-MedLine.d179.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s3" text="NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. ">
        <entity id="DDI-MedLine.d179.s3.e0" charOffset="84-92"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s3.e1" charOffset="97-105"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s3.p0" e1="DDI-MedLine.d179.s3.e0"
            e2="DDI-MedLine.d179.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s4" text="After exposure, the cell viability was measured by MTT assay, cell cycle distribution was analyzed by flow cytometry, and alterations in signaling pathway were determined by immunoblotting. "/>
    <sentence id="DDI-MedLine.d179.s5" text="Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. ">
        <entity id="DDI-MedLine.d179.s5.e0" charOffset="0-8" type="drug" text="Sunitinib"/>
        <entity id="DDI-MedLine.d179.s5.e1" charOffset="118-126"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s5.p0" e1="DDI-MedLine.d179.s5.e0"
            e2="DDI-MedLine.d179.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s6" text="Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ">
        <entity id="DDI-MedLine.d179.s6.e0" charOffset="37-45"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s6.e1" charOffset="51-59"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s6.p0" e1="DDI-MedLine.d179.s6.e0"
            e2="DDI-MedLine.d179.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s7" text="When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ">
        <entity id="DDI-MedLine.d179.s7.e0" charOffset="27-35"
            type="drug" text="docetaxel"/>
        <entity id="DDI-MedLine.d179.s7.e1" charOffset="49-57"
            type="drug" text="sunitinib"/>
        <pair id="DDI-MedLine.d179.s7.p0" e1="DDI-MedLine.d179.s7.e0"
            e2="DDI-MedLine.d179.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s8" text="The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ">
        <entity id="DDI-MedLine.d179.s8.e0" charOffset="102-110"
            type="drug" text="docetaxel"/>
        <entity id="DDI-MedLine.d179.s8.e1" charOffset="179-187"
            type="drug" text="sunitinib"/>
        <pair id="DDI-MedLine.d179.s8.p0" e1="DDI-MedLine.d179.s8.e0"
            e2="DDI-MedLine.d179.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d179.s9" text="In contrast, the reverse of this sequential administration resulted in antagonism, which may be due to differential effects on cell cycle arrest. "/>
    <sentence id="DDI-MedLine.d179.s10" text="Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.">
        <entity id="DDI-MedLine.d179.s10.e0" charOffset="0-8"
            type="drug" text="Sunitinib"/>
        <entity id="DDI-MedLine.d179.s10.e1" charOffset="166-174"
            type="drug" text="docetaxel"/>
        <entity id="DDI-MedLine.d179.s10.e2" charOffset="188-196"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s10.e3" charOffset="213-221"
            type="drug" text="sunitinib"/>
        <entity id="DDI-MedLine.d179.s10.e4" charOffset="235-243"
            type="drug" text="docetaxel"/>
        <pair id="DDI-MedLine.d179.s10.p0" e1="DDI-MedLine.d179.s10.e0"
            e2="DDI-MedLine.d179.s10.e1" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p1" e1="DDI-MedLine.d179.s10.e0"
            e2="DDI-MedLine.d179.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p2" e1="DDI-MedLine.d179.s10.e0"
            e2="DDI-MedLine.d179.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p3" e1="DDI-MedLine.d179.s10.e0"
            e2="DDI-MedLine.d179.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p4" e1="DDI-MedLine.d179.s10.e1"
            e2="DDI-MedLine.d179.s10.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d179.s10.p5" e1="DDI-MedLine.d179.s10.e1"
            e2="DDI-MedLine.d179.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p6" e1="DDI-MedLine.d179.s10.e1"
            e2="DDI-MedLine.d179.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p7" e1="DDI-MedLine.d179.s10.e2"
            e2="DDI-MedLine.d179.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p8" e1="DDI-MedLine.d179.s10.e2"
            e2="DDI-MedLine.d179.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d179.s10.p9" e1="DDI-MedLine.d179.s10.e3"
            e2="DDI-MedLine.d179.s10.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s0" text="Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.&#xd;&#xa;">
        <entity id="DDI-MedLine.d204.s0.e0" charOffset="31-42"
            type="drug" text="piperacillin"/>
        <entity id="DDI-MedLine.d204.s0.e1" charOffset="48-60"
            type="drug_n" text="methylglyoxal"/>
        <pair id="DDI-MedLine.d204.s0.p0" e1="DDI-MedLine.d204.s0.e0"
            e2="DDI-MedLine.d204.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s1" text="The dicarbonyl compound methylglyoxal is a natural constituent of Manuka honey produced from Manuka flowers in New Zealand. ">
        <entity id="DDI-MedLine.d204.s1.e0" charOffset="24-36"
            type="drug_n" text="methylglyoxal"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s2" text="It is known to possess both anticancer and antibacterial activity. "/>
    <sentence id="DDI-MedLine.d204.s3" text="Such observations prompted to investigate the ability of methylglyoxal as a potent drug against multidrug resistant Pseudomonas aeruginosa. ">
        <entity id="DDI-MedLine.d204.s3.e0" charOffset="57-69"
            type="drug_n" text="methylglyoxal"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s4" text="A total of 12 test P. "/>
    <sentence id="DDI-MedLine.d204.s5" text="aeruginosa strains isolated from various hospitals were tested for their resistances against many antibiotics, most of which are applied in the treatment of P. ">
        <entity id="DDI-MedLine.d204.s5.e0" charOffset="98-108"
            type="group" text="antibiotics"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s6" text="aeruginosa infections. "/>
    <sentence id="DDI-MedLine.d204.s7" text="Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ">
        <entity id="DDI-MedLine.d204.s7.e0" charOffset="84-95"
            type="drug" text="piperacillin"/>
        <entity id="DDI-MedLine.d204.s7.e1" charOffset="98-110"
            type="drug" text="carbenicillin"/>
        <entity id="DDI-MedLine.d204.s7.e2" charOffset="113-120"
            type="drug" text="amikacin"/>
        <entity id="DDI-MedLine.d204.s7.e3" charOffset="126-138"
            type="drug" text="ciprofloxacin"/>
        <pair id="DDI-MedLine.d204.s7.p0" e1="DDI-MedLine.d204.s7.e0"
            e2="DDI-MedLine.d204.s7.e1" ddi="false"/>
        <pair id="DDI-MedLine.d204.s7.p1" e1="DDI-MedLine.d204.s7.e0"
            e2="DDI-MedLine.d204.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d204.s7.p2" e1="DDI-MedLine.d204.s7.e0"
            e2="DDI-MedLine.d204.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d204.s7.p3" e1="DDI-MedLine.d204.s7.e1"
            e2="DDI-MedLine.d204.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d204.s7.p4" e1="DDI-MedLine.d204.s7.e1"
            e2="DDI-MedLine.d204.s7.e3" ddi="false"/>
        <pair id="DDI-MedLine.d204.s7.p5" e1="DDI-MedLine.d204.s7.e2"
            e2="DDI-MedLine.d204.s7.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s8" text="Following multiple experimentations it was observed that methylglyoxal was also antimicrobic against all the strains at comparable levels. ">
        <entity id="DDI-MedLine.d204.s8.e0" charOffset="57-69"
            type="drug_n" text="methylglyoxal"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s9" text="Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ">
        <entity id="DDI-MedLine.d204.s9.e0" charOffset="70-82"
            type="drug_n" text="methylglyoxal"/>
        <entity id="DDI-MedLine.d204.s9.e1" charOffset="88-99"
            type="drug" text="piperacillin"/>
        <pair id="DDI-MedLine.d204.s9.p0" e1="DDI-MedLine.d204.s9.e0"
            e2="DDI-MedLine.d204.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d204.s10" text="The fractional inhibitory concentration index of this combination evaluated by checkerboard analysis, was 0.5, which confirmed synergism between the pair. "/>
    <sentence id="DDI-MedLine.d204.s11" text="Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.">
        <entity id="DDI-MedLine.d204.s11.e0" charOffset="30-42"
            type="drug_n" text="methylglyoxal"/>
        <entity id="DDI-MedLine.d204.s11.e1" charOffset="62-74"
            type="drug" text="carbenicillin"/>
        <entity id="DDI-MedLine.d204.s11.e2" charOffset="80-87"
            type="drug" text="amikacin"/>
        <pair id="DDI-MedLine.d204.s11.p0" e1="DDI-MedLine.d204.s11.e0"
            e2="DDI-MedLine.d204.s11.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d204.s11.p1" e1="DDI-MedLine.d204.s11.e0"
            e2="DDI-MedLine.d204.s11.e2" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d204.s11.p2" e1="DDI-MedLine.d204.s11.e1"
            e2="DDI-MedLine.d204.s11.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d159.s0" text="Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.">
        <entity id="DDI-MedLine.d159.s0.e0" charOffset="21-38"
            type="drug" text="acetyl-l-carnitine"/>
        <entity id="DDI-MedLine.d159.s0.e1" charOffset="45-61"
            type="drug_n" text="alpha lipoic acid"/>
        <pair id="DDI-MedLine.d159.s0.p0" e1="DDI-MedLine.d159.s0.e0"
            e2="DDI-MedLine.d159.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d159.s1" text="The biotransformation and oxidative stress may contribute to 1,2:3,4-diepoxybutane (DEB)-induced toxicity to human lymphocytes of Fanconi Anemia (FA) patients. "/>
    <sentence id="DDI-MedLine.d159.s2" text="Thus, the identification of putative inhibitors of bioactivation, as well as the determination of the protective role of oxidant defenses, on DEB-induced toxicity, can help to understand what is failing in FA cells. "/>
    <sentence id="DDI-MedLine.d159.s3" text="In the present work we studied the contribution of several biochemical pathways for DEB-induced acute toxicity in human lymphocyte suspensions, by using inhibitors of epoxide hydrolases, inhibitors of protective enzymes as glutathione S-transferase and catalase, the depletion of glutathione (GSH), and the inhibition of protein synthesis; "/>
    <sentence id="DDI-MedLine.d159.s4" text="and a variety of putative protective compounds, including antioxidants, and mitochondrial protective agents. "/>
    <sentence id="DDI-MedLine.d159.s5" text="The present study reports two novel findings: (i) it was clearly evidenced, for the first time, that the acute exposure of freshly isolated human lymphocytes to DEB results in severe GSH depletion and loss of ATP, followed by cell death; "/>
    <sentence id="DDI-MedLine.d159.s6" text="(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.">
        <entity id="DDI-MedLine.d159.s6.e0" charOffset="5-22"
            type="drug" text="acetyl-l-carnitine"/>
        <entity id="DDI-MedLine.d159.s6.e1" charOffset="115-131"
            type="drug" text="alpha-lipoic acid"/>
        <pair id="DDI-MedLine.d159.s6.p0" e1="DDI-MedLine.d159.s6.e0"
            e2="DDI-MedLine.d159.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d159.s7" text="Collectively, these findings contribute to increase our knowledge of DEB-induce toxicity and will be very useful when applied in studies with lymphocytes from FA patients, in order to find out a protective agent against spontaneous and DEB-induced chromosome instability."/>
    <sentence id="DDI-MedLine.d214.s0" text="[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].&#xd;&#xa;">
        <entity id="DDI-MedLine.d214.s0.e0" charOffset="14-22"
            type="drug_n" text="hemantane"/>
        <entity id="DDI-MedLine.d214.s0.e1" charOffset="28-38"
            type="drug" text="doxycycline"/>
        <pair id="DDI-MedLine.d214.s0.p0" e1="DDI-MedLine.d214.s0.e0"
            e2="DDI-MedLine.d214.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d214.s1" text="The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ">
        <entity id="DDI-MedLine.d214.s1.e0" charOffset="15-36"
            type="group" text="anti-parkinsonian drug"/>
        <entity id="DDI-MedLine.d214.s1.e1" charOffset="38-46"
            type="drug_n" text="hemantane"/>
        <entity id="DDI-MedLine.d214.s1.e2" charOffset="49-78"
            type="drug_n" text="(2-adamantyl)hexamethylenimine"/>
        <pair id="DDI-MedLine.d214.s1.p0" e1="DDI-MedLine.d214.s1.e0"
            e2="DDI-MedLine.d214.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d214.s1.p1" e1="DDI-MedLine.d214.s1.e0"
            e2="DDI-MedLine.d214.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d214.s1.p2" e1="DDI-MedLine.d214.s1.e1"
            e2="DDI-MedLine.d214.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d214.s2" text="and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ">
        <entity id="DDI-MedLine.d214.s2.e0" charOffset="7-21"
            type="group" text="antibiotic drug"/>
        <entity id="DDI-MedLine.d214.s2.e1" charOffset="23-33"
            type="drug" text="doxycycline"/>
        <entity id="DDI-MedLine.d214.s2.e2" charOffset="85-128"
            type="drug_n" text="1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"/>
        <entity id="DDI-MedLine.d214.s2.e3" charOffset="131-134"
            type="drug_n" text="MPTP"/>
        <pair id="DDI-MedLine.d214.s2.p0" e1="DDI-MedLine.d214.s2.e0"
            e2="DDI-MedLine.d214.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d214.s2.p1" e1="DDI-MedLine.d214.s2.e0"
            e2="DDI-MedLine.d214.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d214.s2.p2" e1="DDI-MedLine.d214.s2.e0"
            e2="DDI-MedLine.d214.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d214.s2.p3" e1="DDI-MedLine.d214.s2.e1"
            e2="DDI-MedLine.d214.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d214.s2.p4" e1="DDI-MedLine.d214.s2.e1"
            e2="DDI-MedLine.d214.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d214.s2.p5" e1="DDI-MedLine.d214.s2.e2"
            e2="DDI-MedLine.d214.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d214.s3" text="were studied in elevated plus maze test on C57BL/6 mice. "/>
    <sentence id="DDI-MedLine.d214.s4" text="On second day after injection, MPTP decreased the locomot or activity in comparison to saline. ">
        <entity id="DDI-MedLine.d214.s4.e0" charOffset="31-34"
            type="drug_n" text="MPTP"/>
    </sentence>
    <sentence id="DDI-MedLine.d214.s5" text="Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ">
        <entity id="DDI-MedLine.d214.s5.e0" charOffset="24-32"
            type="drug_n" text="hemantane"/>
        <entity id="DDI-MedLine.d214.s5.e1" charOffset="37-47"
            type="drug" text="doxycycline"/>
        <pair id="DDI-MedLine.d214.s5.p0" e1="DDI-MedLine.d214.s5.e0"
            e2="DDI-MedLine.d214.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d214.s6" text="The results obtained confirm the role of inflammatory processes in parkinsonism and suggest expediency of combined pharmacotherapy of neurodegenerative diseases."/>
    <sentence id="DDI-MedLine.d194.s0" text="The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.&#xd;&#xa;">
        <entity id="DDI-MedLine.d194.s0.e0" charOffset="25-33"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s0.e1" charOffset="44-53"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s0.p0" e1="DDI-MedLine.d194.s0.e0"
            e2="DDI-MedLine.d194.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s1" text="Less than 50% of ovarian cancers respond to paclitaxel. ">
        <entity id="DDI-MedLine.d194.s1.e0" charOffset="44-53"
            type="drug" text="paclitaxel"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s2" text="Effective strategies are needed to enhance paclitaxel sensitivity.">
        <entity id="DDI-MedLine.d194.s2.e0" charOffset="43-52"
            type="drug" text="paclitaxel"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s3" text="A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. ">
        <entity id="DDI-MedLine.d194.s3.e0" charOffset="80-89"
            type="drug" text="paclitaxel"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s4" text="The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. ">
        <entity id="DDI-MedLine.d194.s4.e0" charOffset="14-22"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s4.e1" charOffset="65-74"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s4.p0" e1="DDI-MedLine.d194.s4.e0"
            e2="DDI-MedLine.d194.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s5" text="The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ">
        <entity id="DDI-MedLine.d194.s5.e0" charOffset="64-72"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s5.e1" charOffset="78-87"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s5.p0" e1="DDI-MedLine.d194.s5.e0"
            e2="DDI-MedLine.d194.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s6" text="All statistical tests were two-sided. "/>
    <sentence id="DDI-MedLine.d194.s7" text="Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. ">
        <entity id="DDI-MedLine.d194.s7.e0" charOffset="60-69"
            type="drug" text="paclitaxel"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s8" text="The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control siRNA. ">
        <entity id="DDI-MedLine.d194.s8.e0" charOffset="50-59"
            type="drug" text="paclitaxel"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s9" text="HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ">
        <entity id="DDI-MedLine.d194.s9.e0" charOffset="23-31"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s9.e1" charOffset="38-47"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s9.p0" e1="DDI-MedLine.d194.s9.e0"
            e2="DDI-MedLine.d194.s9.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s10" text="Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ">
        <entity id="DDI-MedLine.d194.s10.e0" charOffset="45-53"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s10.e1" charOffset="60-69"
            type="drug" text="paclitaxel"/>
        <entity id="DDI-MedLine.d194.s10.e2" charOffset="171-179"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s10.e3" charOffset="183-192"
            type="drug" text="paclitaxel"/>
        <entity id="DDI-MedLine.d194.s10.e4" charOffset="197-206"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s10.p0" e1="DDI-MedLine.d194.s10.e0"
            e2="DDI-MedLine.d194.s10.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d194.s10.p1" e1="DDI-MedLine.d194.s10.e0"
            e2="DDI-MedLine.d194.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p2" e1="DDI-MedLine.d194.s10.e0"
            e2="DDI-MedLine.d194.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p3" e1="DDI-MedLine.d194.s10.e0"
            e2="DDI-MedLine.d194.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p4" e1="DDI-MedLine.d194.s10.e1"
            e2="DDI-MedLine.d194.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p5" e1="DDI-MedLine.d194.s10.e1"
            e2="DDI-MedLine.d194.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p6" e1="DDI-MedLine.d194.s10.e1"
            e2="DDI-MedLine.d194.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p7" e1="DDI-MedLine.d194.s10.e2"
            e2="DDI-MedLine.d194.s10.e3" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p8" e1="DDI-MedLine.d194.s10.e2"
            e2="DDI-MedLine.d194.s10.e4" ddi="false"/>
        <pair id="DDI-MedLine.d194.s10.p9" e1="DDI-MedLine.d194.s10.e3"
            e2="DDI-MedLine.d194.s10.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s11" text="dasatinib + paclitaxel vs. ">
        <entity id="DDI-MedLine.d194.s11.e0" charOffset="0-8"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s11.e1" charOffset="12-21"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s11.p0" e1="DDI-MedLine.d194.s11.e0"
            e2="DDI-MedLine.d194.s11.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s12" text="dasatinib: 0.28 vs. ">
        <entity id="DDI-MedLine.d194.s12.e0" charOffset="0-8"
            type="drug" text="dasatinib"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s13" text="0.55 cm3, difference = 0.27 cm3, 95% CI = 0.21 to 0.33 cm3, P = .035). "/>
    <sentence id="DDI-MedLine.d194.s14" text="Combined treatment induced more TUNEL-positive apoptotic cells than did either agent alone. "/>
    <sentence id="DDI-MedLine.d194.s15" text="The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ">
        <entity id="DDI-MedLine.d194.s15.e0" charOffset="43-51"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s15.e1" charOffset="58-67"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s15.p0" e1="DDI-MedLine.d194.s15.e0"
            e2="DDI-MedLine.d194.s15.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s16" text="Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ">
        <entity id="DDI-MedLine.d194.s16.e0" charOffset="82-90"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s16.e1" charOffset="133-142"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s16.p0" e1="DDI-MedLine.d194.s16.e0"
            e2="DDI-MedLine.d194.s16.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d194.s17" text="Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.">
        <entity id="DDI-MedLine.d194.s17.e0" charOffset="63-71"
            type="drug" text="dasatinib"/>
        <entity id="DDI-MedLine.d194.s17.e1" charOffset="82-91"
            type="drug" text="paclitaxel"/>
        <pair id="DDI-MedLine.d194.s17.p0" e1="DDI-MedLine.d194.s17.e0"
            e2="DDI-MedLine.d194.s17.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d211.s0" text="Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.&#xd;&#xa;">
        <entity id="DDI-MedLine.d211.s0.e0" charOffset="17-28"
            type="drug" text="lenalidomide"/>
        <entity id="DDI-MedLine.d211.s0.e1" charOffset="34-40"
            type="drug" text="CCI-779"/>
        <entity id="DDI-MedLine.d211.s0.e2" charOffset="99-110"
            type="drug" text="lenalidomide"/>
        <entity id="DDI-MedLine.d211.s0.e3" charOffset="112-118"
            type="drug" text="CCI-779"/>
        <pair id="DDI-MedLine.d211.s0.p0" e1="DDI-MedLine.d211.s0.e0"
            e2="DDI-MedLine.d211.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d211.s0.p1" e1="DDI-MedLine.d211.s0.e0"
            e2="DDI-MedLine.d211.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d211.s0.p2" e1="DDI-MedLine.d211.s0.e0"
            e2="DDI-MedLine.d211.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d211.s0.p3" e1="DDI-MedLine.d211.s0.e1"
            e2="DDI-MedLine.d211.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d211.s0.p4" e1="DDI-MedLine.d211.s0.e1"
            e2="DDI-MedLine.d211.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d211.s0.p5" e1="DDI-MedLine.d211.s0.e2"
            e2="DDI-MedLine.d211.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d211.s1" text="Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. ">
        <entity id="DDI-MedLine.d211.s1.e0" charOffset="127-139"
            type="drug" text="dexamethasone"/>
    </sentence>
    <sentence id="DDI-MedLine.d211.s2" text="The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.">
        <entity id="DDI-MedLine.d211.s2.e0" charOffset="31-42"
            type="drug" text="lenalidomide"/>
        <entity id="DDI-MedLine.d211.s2.e1" charOffset="68-74"
            type="drug" text="CCI-779"/>
        <pair id="DDI-MedLine.d211.s2.p0" e1="DDI-MedLine.d211.s2.e0"
            e2="DDI-MedLine.d211.s2.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s0" text="Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.&#xd;&#xa;">
        <entity id="DDI-MedLine.d154.s0.e0" charOffset="77-100"
            type="group" text="avian influenza vaccines"/>
        <entity id="DDI-MedLine.d154.s0.e1" charOffset="128-157"
            type="drug_n" text="ginseng stem-and-leaf saponins"/>
        <pair id="DDI-MedLine.d154.s0.p0" e1="DDI-MedLine.d154.s0.e0"
            e2="DDI-MedLine.d154.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s1" text="Newcastle disease (ND) and avian influenza (AI) are common in the poultry industry. "/>
    <sentence id="DDI-MedLine.d154.s2" text="The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ">
        <entity id="DDI-MedLine.d154.s2.e0" charOffset="81-110"
            type="drug_n" text="ginseng stem-and-leaf saponins"/>
        <entity id="DDI-MedLine.d154.s2.e1" charOffset="113-116"
            type="drug_n" text="GSLS"/>
        <entity id="DDI-MedLine.d154.s2.e2" charOffset="166-179;188-195"
            type="drug" text="inactivated ND vaccines"/>
        <entity id="DDI-MedLine.d154.s2.e3"
            charOffset="166-176;185-186;188-195" type="drug" text="inactivated AI vaccines"/>
        <pair id="DDI-MedLine.d154.s2.p0" e1="DDI-MedLine.d154.s2.e0"
            e2="DDI-MedLine.d154.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d154.s2.p1" e1="DDI-MedLine.d154.s2.e0"
            e2="DDI-MedLine.d154.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d154.s2.p2" e1="DDI-MedLine.d154.s2.e0"
            e2="DDI-MedLine.d154.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d154.s2.p3" e1="DDI-MedLine.d154.s2.e1"
            e2="DDI-MedLine.d154.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d154.s2.p4" e1="DDI-MedLine.d154.s2.e1"
            e2="DDI-MedLine.d154.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d154.s2.p5" e1="DDI-MedLine.d154.s2.e2"
            e2="DDI-MedLine.d154.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s3" text="In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. ">
        <entity id="DDI-MedLine.d154.s3.e0" charOffset="40-43"
            type="drug_n" text="GSLS"/>
        <entity id="DDI-MedLine.d154.s3.e1" charOffset="145-166"
            type="drug" text="inactivated ND vaccine"/>
        <pair id="DDI-MedLine.d154.s3.p0" e1="DDI-MedLine.d154.s3.e0"
            e2="DDI-MedLine.d154.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s4" text="Results showed that GSLS significantly increased the antibody level against ND in the serum of chickens. ">
        <entity id="DDI-MedLine.d154.s4.e0" charOffset="20-23"
            type="drug_n" text="GSLS"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s5" text="In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ">
        <entity id="DDI-MedLine.d154.s5.e0" charOffset="37-40"
            type="drug_n" text="GSLS"/>
        <entity id="DDI-MedLine.d154.s5.e1" charOffset="87-109"
            type="drug" text="inactivated AI vaccines"/>
        <pair id="DDI-MedLine.d154.s5.p0" e1="DDI-MedLine.d154.s5.e0"
            e2="DDI-MedLine.d154.s5.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d154.s6" text="Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.">
        <entity id="DDI-MedLine.d154.s6.e0" charOffset="26-29"
            type="drug_n" text="GSLS"/>
        <entity id="DDI-MedLine.d154.s6.e1" charOffset="96-99"
            type="drug_n" text="GSLS"/>
        <pair id="DDI-MedLine.d154.s6.p0" e1="DDI-MedLine.d154.s6.e0"
            e2="DDI-MedLine.d154.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d147.s0" text="Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.&#xd;&#xa;">
        <entity id="DDI-MedLine.d147.s0.e0" charOffset="15-25"
            type="drug" text="dacarbazine"/>
        <entity id="DDI-MedLine.d147.s0.e1" charOffset="31-36"
            type="drug_n" text="imexon"/>
        <pair id="DDI-MedLine.d147.s0.p0" e1="DDI-MedLine.d147.s0.e0"
            e2="DDI-MedLine.d147.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d147.s1" text="We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.">
        <entity id="DDI-MedLine.d147.s1.e0" charOffset="67-77"
            type="drug" text="dacarbazine"/>
        <entity id="DDI-MedLine.d147.s1.e1" charOffset="80-83"
            type="drug" text="DTIC"/>
        <entity id="DDI-MedLine.d147.s1.e2" charOffset="107-112"
            type="drug" text="imexon"/>
        <pair id="DDI-MedLine.d147.s1.p0" e1="DDI-MedLine.d147.s1.e0"
            e2="DDI-MedLine.d147.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d147.s1.p1" e1="DDI-MedLine.d147.s1.e0"
            e2="DDI-MedLine.d147.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d147.s1.p2" e1="DDI-MedLine.d147.s1.e1"
            e2="DDI-MedLine.d147.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d147.s2" text="The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ">
        <entity id="DDI-MedLine.d147.s2.e0" charOffset="14-17"
            type="drug" text="DTIC"/>
        <entity id="DDI-MedLine.d147.s2.e1" charOffset="23-28"
            type="drug" text="imexon"/>
        <pair id="DDI-MedLine.d147.s2.p0" e1="DDI-MedLine.d147.s2.e0"
            e2="DDI-MedLine.d147.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d147.s3" text="Pharmacokinetic and antitumor effects were evaluated in mice. "/>
    <sentence id="DDI-MedLine.d147.s4" text="Growth inhibition in vitro was additive with the two drugs. "/>
    <sentence id="DDI-MedLine.d147.s5" text="There was no effect on drug uptake or on the number of DNA strand breaks. "/>
    <sentence id="DDI-MedLine.d147.s6" text="There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. ">
        <entity id="DDI-MedLine.d147.s6.e0" charOffset="69-74"
            type="drug" text="imexon"/>
        <entity id="DDI-MedLine.d147.s6.e1" charOffset="84-87"
            type="drug" text="DTIC"/>
        <pair id="DDI-MedLine.d147.s6.p0" e1="DDI-MedLine.d147.s6.e0"
            e2="DDI-MedLine.d147.s6.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d147.s7" text="Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo. "/>
    <sentence id="DDI-MedLine.d147.s8" text="Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.">
        <entity id="DDI-MedLine.d147.s8.e0" charOffset="0-5" type="drug" text="Imexon"/>
        <entity id="DDI-MedLine.d147.s8.e1" charOffset="11-21"
            type="drug" text="dacarbazine"/>
        <pair id="DDI-MedLine.d147.s8.p0" e1="DDI-MedLine.d147.s8.e0"
            e2="DDI-MedLine.d147.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s0" text="Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.&#xd;&#xa;">
        <entity id="DDI-MedLine.d164.s0.e0" charOffset="0-8" type="drug" text="Lapatinib"/>
        <entity id="DDI-MedLine.d164.s0.e1" charOffset="19-27"
            type="brand" text="herceptin"/>
        <pair id="DDI-MedLine.d164.s0.p0" e1="DDI-MedLine.d164.s0.e0"
            e2="DDI-MedLine.d164.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s1" text="Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.">
        <entity id="DDI-MedLine.d164.s1.e0" charOffset="41-49"
            type="drug" text="lapatinib"/>
        <entity id="DDI-MedLine.d164.s1.e1" charOffset="65-73"
            type="brand" text="Herceptin"/>
        <entity id="DDI-MedLine.d164.s1.e2" charOffset="133-141"
            type="drug" text="lapatinib"/>
        <entity id="DDI-MedLine.d164.s1.e3" charOffset="167-175"
            type="brand" text="Herceptin"/>
        <pair id="DDI-MedLine.d164.s1.p0" e1="DDI-MedLine.d164.s1.e0"
            e2="DDI-MedLine.d164.s1.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d164.s1.p1" e1="DDI-MedLine.d164.s1.e0"
            e2="DDI-MedLine.d164.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d164.s1.p2" e1="DDI-MedLine.d164.s1.e0"
            e2="DDI-MedLine.d164.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d164.s1.p3" e1="DDI-MedLine.d164.s1.e1"
            e2="DDI-MedLine.d164.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d164.s1.p4" e1="DDI-MedLine.d164.s1.e1"
            e2="DDI-MedLine.d164.s1.e3" ddi="false"/>
        <pair id="DDI-MedLine.d164.s1.p5" e1="DDI-MedLine.d164.s1.e2"
            e2="DDI-MedLine.d164.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s2" text="We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ">
        <entity id="DDI-MedLine.d164.s2.e0" charOffset="17-25"
            type="drug" text="lapatinib"/>
        <entity id="DDI-MedLine.d164.s2.e1" charOffset="42-50"
            type="brand" text="Herceptin"/>
        <entity id="DDI-MedLine.d164.s2.e2" charOffset="111-119"
            type="brand" text="Herceptin"/>
        <pair id="DDI-MedLine.d164.s2.p0" e1="DDI-MedLine.d164.s2.e0"
            e2="DDI-MedLine.d164.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d164.s2.p1" e1="DDI-MedLine.d164.s2.e0"
            e2="DDI-MedLine.d164.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d164.s2.p2" e1="DDI-MedLine.d164.s2.e1"
            e2="DDI-MedLine.d164.s2.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s3" text="In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. ">
        <entity id="DDI-MedLine.d164.s3.e0" charOffset="22-30"
            type="drug" text="lapatinib"/>
        <entity id="DDI-MedLine.d164.s3.e1" charOffset="149-157"
            type="brand" text="Herceptin"/>
        <pair id="DDI-MedLine.d164.s3.p0" e1="DDI-MedLine.d164.s3.e0"
            e2="DDI-MedLine.d164.s3.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s4" text="Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ">
        <entity id="DDI-MedLine.d164.s4.e0" charOffset="56-64"
            type="brand" text="Herceptin"/>
        <entity id="DDI-MedLine.d164.s4.e1" charOffset="86-94"
            type="drug" text="lapatinib"/>
        <pair id="DDI-MedLine.d164.s4.p0" e1="DDI-MedLine.d164.s4.e0"
            e2="DDI-MedLine.d164.s4.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d164.s5" text="Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.">
        <entity id="DDI-MedLine.d164.s5.e0" charOffset="0-8" type="drug" text="Lapatinib"/>
        <entity id="DDI-MedLine.d164.s5.e1" charOffset="44-52"
            type="brand" text="Herceptin"/>
        <entity id="DDI-MedLine.d164.s5.e2" charOffset="68-76"
            type="brand" text="Herceptin"/>
        <pair id="DDI-MedLine.d164.s5.p0" e1="DDI-MedLine.d164.s5.e0"
            e2="DDI-MedLine.d164.s5.e1" ddi="false"/>
        <pair id="DDI-MedLine.d164.s5.p1" e1="DDI-MedLine.d164.s5.e0"
            e2="DDI-MedLine.d164.s5.e2" ddi="false"/>
        <pair id="DDI-MedLine.d164.s5.p2" e1="DDI-MedLine.d164.s5.e1"
            e2="DDI-MedLine.d164.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s0" text="Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.&#xd;&#xa;">
        <entity id="DDI-MedLine.d201.s0.e0" charOffset="21-26"
            type="drug_n" text="CRM197"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s1" text="The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; "/>
    <sentence id="DDI-MedLine.d201.s2" text="thus, novel, targeted therapies are urgently needed. "/>
    <sentence id="DDI-MedLine.d201.s3" text="Recently, we showed that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family, is a promising target for the treatment of various types of cancer. "/>
    <sentence id="DDI-MedLine.d201.s4" text="The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). ">
        <entity id="DDI-MedLine.d201.s4.e0" charOffset="180-206"
            type="drug_n" text="cross-reacting material 197"/>
        <entity id="DDI-MedLine.d201.s4.e1" charOffset="209-214"
            type="drug_n" text="CRM197"/>
        <pair id="DDI-MedLine.d201.s4.p0" e1="DDI-MedLine.d201.s4.e0"
            e2="DDI-MedLine.d201.s4.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s5" text="We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. ">
        <entity id="DDI-MedLine.d201.s5.e0" charOffset="88-93"
            type="drug_n" text="CRM197"/>
        <entity id="DDI-MedLine.d201.s5.e1" charOffset="139-154"
            type="group" text="anticancer agent"/>
        <pair id="DDI-MedLine.d201.s5.p0" e1="DDI-MedLine.d201.s5.e0"
            e2="DDI-MedLine.d201.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s6" text="The expression of EGFR and EGFR ligands was determined by flow cytometry, RT-PCR and real-time quantitative PCR. "/>
    <sentence id="DDI-MedLine.d201.s7" text="Induction of apoptosis was assessed by TUNEL assay. "/>
    <sentence id="DDI-MedLine.d201.s8" text="HB-EGF was strongly expressed by T-ALL cell lines, and the expression of both HB-EGF and EGFR was enhanced by doxorubicin. ">
        <entity id="DDI-MedLine.d201.s8.e0" charOffset="110-120"
            type="drug" text="doxorubicin"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s9" text="CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ">
        <entity id="DDI-MedLine.d201.s9.e0" charOffset="0-5"
            type="drug_n" text="CRM197"/>
        <entity id="DDI-MedLine.d201.s9.e1" charOffset="62-67"
            type="drug_n" text="CRM197"/>
        <entity id="DDI-MedLine.d201.s9.e2" charOffset="74-84"
            type="drug" text="doxorubicin"/>
        <pair id="DDI-MedLine.d201.s9.p0" e1="DDI-MedLine.d201.s9.e0"
            e2="DDI-MedLine.d201.s9.e1" ddi="false"/>
        <pair id="DDI-MedLine.d201.s9.p1" e1="DDI-MedLine.d201.s9.e0"
            e2="DDI-MedLine.d201.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d201.s9.p2" e1="DDI-MedLine.d201.s9.e1"
            e2="DDI-MedLine.d201.s9.e2" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d201.s10" text="These results suggest that HB-EGF is a promising therapeutic target for T-ALL."/>
    <sentence id="DDI-MedLine.d227.s0" text="Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.&#xd;&#xa;">
        <entity id="DDI-MedLine.d227.s0.e0" charOffset="0-8" type="drug" text="Ephedrine"/>
        <entity id="DDI-MedLine.d227.s0.e1" charOffset="49-63"
            type="drug" text="dexmedetomidine"/>
        <pair id="DDI-MedLine.d227.s0.p0" e1="DDI-MedLine.d227.s0.e0"
            e2="DDI-MedLine.d227.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s1" text="Dexmedetomidine, a highly selective alpha-2-adrenoceptor agonist, was recently introduced into clinical practice for its sedative and analgesic properties. ">
        <entity id="DDI-MedLine.d227.s1.e0" charOffset="0-14"
            type="drug" text="Dexmedetomidine"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s2" text="The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.">
        <entity id="DDI-MedLine.d227.s2.e0" charOffset="75-83"
            type="drug" text="ephedrine"/>
        <entity id="DDI-MedLine.d227.s2.e1" charOffset="103-117"
            type="drug" text="dexmedetomidine"/>
        <pair id="DDI-MedLine.d227.s2.p0" e1="DDI-MedLine.d227.s2.e0"
            e2="DDI-MedLine.d227.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s3" text="In both sexes of swiss albino mice; "/>
    <sentence id="DDI-MedLine.d227.s4" text="antinociception was assessed with hot-plate test and the locomotor, exploratory activities were assessed with holed open field test. "/>
    <sentence id="DDI-MedLine.d227.s5" text="The animals were received; "/>
    <sentence id="DDI-MedLine.d227.s6" text="saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ">
        <entity id="DDI-MedLine.d227.s6.e0" charOffset="17-25"
            type="drug" text="ephedrine"/>
        <entity id="DDI-MedLine.d227.s6.e1" charOffset="59-73"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-MedLine.d227.s6.e2" charOffset="93-101"
            type="drug" text="ephedrine"/>
        <entity id="DDI-MedLine.d227.s6.e3" charOffset="118-132"
            type="drug" text="dexmedetomidine"/>
        <pair id="DDI-MedLine.d227.s6.p0" e1="DDI-MedLine.d227.s6.e0"
            e2="DDI-MedLine.d227.s6.e1" ddi="false"/>
        <pair id="DDI-MedLine.d227.s6.p1" e1="DDI-MedLine.d227.s6.e0"
            e2="DDI-MedLine.d227.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d227.s6.p2" e1="DDI-MedLine.d227.s6.e0"
            e2="DDI-MedLine.d227.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d227.s6.p3" e1="DDI-MedLine.d227.s6.e1"
            e2="DDI-MedLine.d227.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d227.s6.p4" e1="DDI-MedLine.d227.s6.e1"
            e2="DDI-MedLine.d227.s6.e3" ddi="false"/>
        <pair id="DDI-MedLine.d227.s6.p5" e1="DDI-MedLine.d227.s6.e2"
            e2="DDI-MedLine.d227.s6.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s7" text="In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ">
        <entity id="DDI-MedLine.d227.s7.e0" charOffset="64-78"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-MedLine.d227.s7.e1" charOffset="96-104"
            type="drug" text="ephedrine"/>
        <entity id="DDI-MedLine.d227.s7.e2" charOffset="205-219"
            type="drug" text="dexmedetomidine"/>
        <pair id="DDI-MedLine.d227.s7.p0" e1="DDI-MedLine.d227.s7.e0"
            e2="DDI-MedLine.d227.s7.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d227.s7.p1" e1="DDI-MedLine.d227.s7.e0"
            e2="DDI-MedLine.d227.s7.e2" ddi="false"/>
        <pair id="DDI-MedLine.d227.s7.p2" e1="DDI-MedLine.d227.s7.e1"
            e2="DDI-MedLine.d227.s7.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s8" text="At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ">
        <entity id="DDI-MedLine.d227.s8.e0" charOffset="53-67"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-MedLine.d227.s8.e1" charOffset="89-97"
            type="drug" text="ephedrine"/>
        <pair id="DDI-MedLine.d227.s8.p0" e1="DDI-MedLine.d227.s8.e0"
            e2="DDI-MedLine.d227.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-MedLine.d227.s9" text="We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.">
        <entity id="DDI-MedLine.d227.s9.e0" charOffset="49-63"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-MedLine.d227.s9.e1" charOffset="70-78"
            type="drug" text="ephedrine"/>
        <entity id="DDI-MedLine.d227.s9.e2" charOffset="183-197"
            type="drug" text="dexmedetomidine"/>
        <entity id="DDI-MedLine.d227.s9.e3" charOffset="205-213"
            type="group" text="analgesic"/>
        <pair id="DDI-MedLine.d227.s9.p0" e1="DDI-MedLine.d227.s9.e0"
            e2="DDI-MedLine.d227.s9.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d227.s9.p1" e1="DDI-MedLine.d227.s9.e0"
            e2="DDI-MedLine.d227.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d227.s9.p2" e1="DDI-MedLine.d227.s9.e0"
            e2="DDI-MedLine.d227.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d227.s9.p3" e1="DDI-MedLine.d227.s9.e1"
            e2="DDI-MedLine.d227.s9.e2" ddi="false"/>
        <pair id="DDI-MedLine.d227.s9.p4" e1="DDI-MedLine.d227.s9.e1"
            e2="DDI-MedLine.d227.s9.e3" ddi="false"/>
        <pair id="DDI-MedLine.d227.s9.p5" e1="DDI-MedLine.d227.s9.e2"
            e2="DDI-MedLine.d227.s9.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s0" text="[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]">
        <entity id="DDI-MedLine.d200.s0.e0" charOffset="31-40"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s0.e1" charOffset="42-50"
            type="drug" text="valsartan"/>
        <pair id="DDI-MedLine.d200.s0.p0" e1="DDI-MedLine.d200.s0.e0"
            e2="DDI-MedLine.d200.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s1" text="Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ">
        <entity id="DDI-MedLine.d200.s1.e0" charOffset="35-44"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s1.e1" charOffset="46-54"
            type="drug" text="valsartan"/>
        <pair id="DDI-MedLine.d200.s1.p0" e1="DDI-MedLine.d200.s1.e0"
            e2="DDI-MedLine.d200.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s2" text="All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). ">
        <entity id="DDI-MedLine.d200.s2.e0" charOffset="106-115"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s2.e1" charOffset="117-125"
            type="drug" text="valsartan"/>
        <pair id="DDI-MedLine.d200.s2.p0" e1="DDI-MedLine.d200.s2.e0"
            e2="DDI-MedLine.d200.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s3" text="Correction of antihypertensive therapy was performed by treating physician at daily rounds. ">
        <entity id="DDI-MedLine.d200.s3.e0" charOffset="14-29"
            type="group" text="antihypertensive"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s4" text="Self-control of blood pressure (BP) was performed by patients with the use of UA767PC apparatus. "/>
    <sentence id="DDI-MedLine.d200.s5" text="Results of BP self-control were compared with clinical measurements in order to detect concealed inefficacy of treatment. "/>
    <sentence id="DDI-MedLine.d200.s6" text="Results. "/>
    <sentence id="DDI-MedLine.d200.s7" text="Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). ">
        <entity id="DDI-MedLine.d200.s7.e0" charOffset="56-65"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s7.e1" charOffset="67-75"
            type="drug" text="valsartan"/>
        <pair id="DDI-MedLine.d200.s7.p0" e1="DDI-MedLine.d200.s7.e0"
            e2="DDI-MedLine.d200.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s8" text="But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ">
        <entity id="DDI-MedLine.d200.s8.e0" charOffset="33-42"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s8.e1" charOffset="44-52"
            type="drug" text="valsartan"/>
        <entity id="DDI-MedLine.d200.s8.e2" charOffset="247-268"
            type="group" text="antihypertensive drugs"/>
        <pair id="DDI-MedLine.d200.s8.p0" e1="DDI-MedLine.d200.s8.e0"
            e2="DDI-MedLine.d200.s8.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d200.s8.p1" e1="DDI-MedLine.d200.s8.e0"
            e2="DDI-MedLine.d200.s8.e2" ddi="false"/>
        <pair id="DDI-MedLine.d200.s8.p2" e1="DDI-MedLine.d200.s8.e1"
            e2="DDI-MedLine.d200.s8.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d200.s9" text="Conclusions. "/>
    <sentence id="DDI-MedLine.d200.s10" text="We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.">
        <entity id="DDI-MedLine.d200.s10.e0" charOffset="75-84"
            type="drug" text="amlodipine"/>
        <entity id="DDI-MedLine.d200.s10.e1" charOffset="86-94"
            type="drug" text="valsartan"/>
        <entity id="DDI-MedLine.d200.s10.e2" charOffset="192-213"
            type="group" text="antihypertensive drugs"/>
        <pair id="DDI-MedLine.d200.s10.p0" e1="DDI-MedLine.d200.s10.e0"
            e2="DDI-MedLine.d200.s10.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d200.s10.p1" e1="DDI-MedLine.d200.s10.e0"
            e2="DDI-MedLine.d200.s10.e2" ddi="false"/>
        <pair id="DDI-MedLine.d200.s10.p2" e1="DDI-MedLine.d200.s10.e1"
            e2="DDI-MedLine.d200.s10.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d193.s0" text="Ticagrelor (Brilinta)--better than clopidogrel (Plavix)">
        <entity id="DDI-MedLine.d193.s0.e0" charOffset="0-9" type="drug" text="Ticagrelor"/>
        <entity id="DDI-MedLine.d193.s0.e1" charOffset="12-19"
            type="brand" text="Brilinta"/>
        <entity id="DDI-MedLine.d193.s0.e2" charOffset="35-45"
            type="drug" text="clopidogrel"/>
        <entity id="DDI-MedLine.d193.s0.e3" charOffset="48-53"
            type="brand" text="Plavix"/>
        <pair id="DDI-MedLine.d193.s0.p0" e1="DDI-MedLine.d193.s0.e0"
            e2="DDI-MedLine.d193.s0.e1" ddi="false"/>
        <pair id="DDI-MedLine.d193.s0.p1" e1="DDI-MedLine.d193.s0.e0"
            e2="DDI-MedLine.d193.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s0.p2" e1="DDI-MedLine.d193.s0.e0"
            e2="DDI-MedLine.d193.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d193.s0.p3" e1="DDI-MedLine.d193.s0.e1"
            e2="DDI-MedLine.d193.s0.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s0.p4" e1="DDI-MedLine.d193.s0.e1"
            e2="DDI-MedLine.d193.s0.e3" ddi="false"/>
        <pair id="DDI-MedLine.d193.s0.p5" e1="DDI-MedLine.d193.s0.e2"
            e2="DDI-MedLine.d193.s0.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d193.s1" text="The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ">
        <entity id="DDI-MedLine.d193.s1.e0" charOffset="21-30"
            type="drug" text="ticagrelor"/>
        <entity id="DDI-MedLine.d193.s1.e1" charOffset="33-40"
            type="brand" text="Brilinta"/>
        <entity id="DDI-MedLine.d193.s1.e2" charOffset="64-80"
            type="group" text="antiplatelet drug"/>
        <entity id="DDI-MedLine.d193.s1.e3" charOffset="105-111"
            type="brand" text="aspirin"/>
        <pair id="DDI-MedLine.d193.s1.p0" e1="DDI-MedLine.d193.s1.e0"
            e2="DDI-MedLine.d193.s1.e1" ddi="false"/>
        <pair id="DDI-MedLine.d193.s1.p1" e1="DDI-MedLine.d193.s1.e0"
            e2="DDI-MedLine.d193.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s1.p2" e1="DDI-MedLine.d193.s1.e0"
            e2="DDI-MedLine.d193.s1.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d193.s1.p3" e1="DDI-MedLine.d193.s1.e1"
            e2="DDI-MedLine.d193.s1.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s1.p4" e1="DDI-MedLine.d193.s1.e1"
            e2="DDI-MedLine.d193.s1.e3" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d193.s1.p5" e1="DDI-MedLine.d193.s1.e2"
            e2="DDI-MedLine.d193.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d193.s2" text="It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ">
        <entity id="DDI-MedLine.d193.s2.e0" charOffset="21-31"
            type="drug" text="clopidogrel"/>
        <entity id="DDI-MedLine.d193.s2.e1" charOffset="34-39"
            type="brand" text="Plavix"/>
        <entity id="DDI-MedLine.d193.s2.e2" charOffset="46-54"
            type="drug" text="prasugrel"/>
        <entity id="DDI-MedLine.d193.s2.e3" charOffset="57-63"
            type="brand" text="Effient"/>
        <pair id="DDI-MedLine.d193.s2.p0" e1="DDI-MedLine.d193.s2.e0"
            e2="DDI-MedLine.d193.s2.e1" ddi="false"/>
        <pair id="DDI-MedLine.d193.s2.p1" e1="DDI-MedLine.d193.s2.e0"
            e2="DDI-MedLine.d193.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s2.p2" e1="DDI-MedLine.d193.s2.e0"
            e2="DDI-MedLine.d193.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d193.s2.p3" e1="DDI-MedLine.d193.s2.e1"
            e2="DDI-MedLine.d193.s2.e2" ddi="false"/>
        <pair id="DDI-MedLine.d193.s2.p4" e1="DDI-MedLine.d193.s2.e1"
            e2="DDI-MedLine.d193.s2.e3" ddi="false"/>
        <pair id="DDI-MedLine.d193.s2.p5" e1="DDI-MedLine.d193.s2.e2"
            e2="DDI-MedLine.d193.s2.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d193.s3" text="Clopidogrel is expected to become available generically in the US within the next few months.">
        <entity id="DDI-MedLine.d193.s3.e0" charOffset="0-10"
            type="drug" text="Clopidogrel"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s0" text="Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.&#xd;&#xa;">
        <entity id="DDI-MedLine.d195.s0.e0" charOffset="13-20"
            type="drug_n" text="piperine"/>
        <entity id="DDI-MedLine.d195.s0.e1" charOffset="25-33"
            type="drug" text="ibuprofen"/>
        <pair id="DDI-MedLine.d195.s0.p0" e1="DDI-MedLine.d195.s0.e0"
            e2="DDI-MedLine.d195.s0.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s1" text="Piperine (CAS 94-62-2), an alkaloid obtained from Piper nigrum and P. ">
        <entity id="DDI-MedLine.d195.s1.e0" charOffset="0-7"
            type="drug_n" text="Piperine"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s2" text="longum, is a known inhibitor of various enzymes (CYP isozymes) responsible for biotransformation of drugs. "/>
    <sentence id="DDI-MedLine.d195.s3" text="By inhibiting the metabolism of drugs, piperine improves the bioavailability of drugs. ">
        <entity id="DDI-MedLine.d195.s3.e0" charOffset="39-46"
            type="drug_n" text="piperine"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s4" text="In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ">
        <entity id="DDI-MedLine.d195.s4.e0" charOffset="21-28"
            type="drug_n" text="piperine"/>
        <entity id="DDI-MedLine.d195.s4.e1" charOffset="112-120"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-MedLine.d195.s4.e2" charOffset="140-150"
            type="drug" text="acetic acid"/>
        <entity id="DDI-MedLine.d195.s4.e3" charOffset="210-218"
            type="drug" text="ibuprofen"/>
        <pair id="DDI-MedLine.d195.s4.p0" e1="DDI-MedLine.d195.s4.e0"
            e2="DDI-MedLine.d195.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-MedLine.d195.s4.p1" e1="DDI-MedLine.d195.s4.e0"
            e2="DDI-MedLine.d195.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d195.s4.p2" e1="DDI-MedLine.d195.s4.e0"
            e2="DDI-MedLine.d195.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d195.s4.p3" e1="DDI-MedLine.d195.s4.e1"
            e2="DDI-MedLine.d195.s4.e2" ddi="false"/>
        <pair id="DDI-MedLine.d195.s4.p4" e1="DDI-MedLine.d195.s4.e1"
            e2="DDI-MedLine.d195.s4.e3" ddi="false"/>
        <pair id="DDI-MedLine.d195.s4.p5" e1="DDI-MedLine.d195.s4.e2"
            e2="DDI-MedLine.d195.s4.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s5" text="Ibuprofen plasma concentration was also increased when it was administered with piperine. ">
        <entity id="DDI-MedLine.d195.s5.e0" charOffset="0-8" type="drug" text="Ibuprofen"/>
        <entity id="DDI-MedLine.d195.s5.e1" charOffset="80-87"
            type="drug_n" text="piperine"/>
        <pair id="DDI-MedLine.d195.s5.p0" e1="DDI-MedLine.d195.s5.e0"
            e2="DDI-MedLine.d195.s5.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s6" text="The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. ">
        <entity id="DDI-MedLine.d195.s6.e0" charOffset="44-52"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-MedLine.d195.s6.e1" charOffset="77-84"
            type="drug_n" text="piperine"/>
        <entity id="DDI-MedLine.d195.s6.e2" charOffset="141-149"
            type="drug" text="ibuprofen"/>
        <pair id="DDI-MedLine.d195.s6.p0" e1="DDI-MedLine.d195.s6.e0"
            e2="DDI-MedLine.d195.s6.e1" ddi="true" type="mechanism"/>
        <pair id="DDI-MedLine.d195.s6.p1" e1="DDI-MedLine.d195.s6.e0"
            e2="DDI-MedLine.d195.s6.e2" ddi="false"/>
        <pair id="DDI-MedLine.d195.s6.p2" e1="DDI-MedLine.d195.s6.e1"
            e2="DDI-MedLine.d195.s6.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-MedLine.d195.s7" text="From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.">
        <entity id="DDI-MedLine.d195.s7.e0" charOffset="41-48"
            type="drug_n" text="piperine"/>
        <entity id="DDI-MedLine.d195.s7.e1" charOffset="90-98"
            type="drug" text="ibuprofen"/>
        <pair id="DDI-MedLine.d195.s7.p0" e1="DDI-MedLine.d195.s7.e0"
            e2="DDI-MedLine.d195.s7.e1" ddi="true" type="effect"/>
    </sentence>
</document>
